lidocaine has been researched along with Nerve Pain in 269 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
| Excerpt | Relevance | Reference |
|---|---|---|
| "DSA-guided nerve pulse radiofrequency surgery combined with intravenous lidocaine infusion can effectively relieve pain in patients diagnosed with herpes zoster nerves at the subacute stage, reduce the number of analgesic drugs used in patients, reduce postherpetic neuralgia incidence rate, and improve sleep and quality of life." | 9.51 | Clinical Efficacy of Pulsed Radiofrequency Combined with Intravenous Lidocaine Infusion in the Treatment of Subacute Herpes Zoster Neuralgia. ( He, C; Zhang, W, 2022) |
| "The present study was designed to explore the efficacy of locally injected thiamine or cobalamin in relieving itch or pain and improving the daily living activities among patients with herpetic itching." | 9.19 | Thiamine, cobalamin, locally injected alone or combination for herpetic itching: a single-center randomized controlled trial. ( Lv, ZW; Tang, WZ; Xu, G; Xu, GX, 2014) |
| "The aim of this research is to analyze analgesic efficacy of the 5% lidocaine medicated plaster in two randomized, double-blinded, placebo-controlled, crossover studies in 16 healthy volunteers using capsaicin and sunburn pain models." | 9.15 | Antihyperalgesic efficacy of 5% lidocaine medicated plaster in capsaicin and sunburn pain models--two randomized, double-blinded, placebo-controlled crossover trials in healthy volunteers. ( Draxler, J; Gustorff, B; Hauer, D; Seis, A; Thaler, J, 2011) |
| "To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing." | 9.11 | Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004) |
| "Topical lidocaine is effective in postherpetic neuralgia (PHN)." | 9.11 | Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. ( Baron, R; Binder, A; Kleinert, A; Schattschneider, J; Wasner, G, 2005) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 9.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Topical lidocaine has been recently marketed as a new treatment for post-herpetic neuralgia." | 9.10 | Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. ( Benowitz, NL; Campbell, BJ; Davies, PS; Jacob, P; Rowbotham, M, 2002) |
| "This study compared the efficacy of topical lidocaine patches versus vehicle (placebo) patches applied directly to the painful skin of subjects with postherpetic neuralgia (PHN) utilizing an 'enriched enrollment' study design." | 9.09 | Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. ( Friedman, E; Galer, BS; Perander, J; Rowbotham, MC, 1999) |
| "This study investigated the effect of intravenous lidocaine at two doses (1 mg/kg and 5 mg/kg over 2 hours) and an intravenous saline placebo on the pain and allodynia of postherpetic neuralgia (PHN)." | 9.09 | A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. ( Baranowski, AP; Bonello, E; De Courcey, J, 1999) |
| "A double-blind comparative clinical trial was performed with topical aspirin versus lidocaine for the treatment of 40 patients with postherpetic neuralgia." | 9.09 | Topical acetylsalicylic acid versus lidocaine for postherpetic neuralgia: results of a double-blind comparative clinical trial. ( Szok, D; Tajti, J; Vécsei, L, 1999) |
| "There was minimal change in the degree of pain in the lidocaine-only and control groups during and after the treatment period." | 9.09 | Intrathecal methylprednisolone for intractable postherpetic neuralgia. ( Asai, M; Hashimoto, H; Kimura, F; Kotani, N; Kushikata, T; Matsuki, A; Muraoka, M; Yodono, M, 2000) |
| "Analgesic efficacy of repeated application of a lidocaine cream formula was investigated in herpes zoster patients with subacute pain with no further improvement after continued treatment since their acute stage (S-HZ group, n = 23), and in patients to whom past treatments had not provided adequate pain relief (PHN group, n = 28)." | 9.09 | [Relief of subacute herpetic pain and postherpetic neuralgia with repeated application of 10% lidocaine cream]. ( Iseki, M; Mitsuhata, H; Miyazaki, T; Toriumi, E; Yoshino, K, 2000) |
| "We studied the analgesic efficacy of an intravenous infusion of lidocaine and morphine in 19 adults with well-established postherpetic neuralgia in a three-session, randomized, double-blind, placebo-controlled trial." | 9.07 | Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. ( Fields, HL; Reisner-Keller, LA; Rowbotham, MC, 1991) |
| " Intravenous (iv) lidocaine is beneficial in acute and chronic pain." | 8.93 | The in vitro mechanisms and in vivo efficacy of intravenous lidocaine on the neuroinflammatory response in acute and chronic pain. ( Radema, SA; Scheffer, GJ; Steegers, MA; van Berkum, BF; van den Heuvel, SA; van der Wal, SE; Vaneker, M; Vissers, KC, 2016) |
| " With more and more perianesthesia nurses involved with chronic pain management, it is imperative they understand the special nursing care needs of patients receiving intravenous lidocaine infusion therapy." | 8.12 | Nursing Care During Lidocaine Infusion Therapy for Chronic Pain. ( Wren, KR, 2022) |
| "5% lidocaine medicated plasters are a topical option in the treatment of peripheral neuropathic pain, as monotherapy or as an adjunct to systemic medication." | 7.80 | Use of 5% lidocaine medicated plasters for the treatment of pain in routine hospital practice: patient reported pain, functioning and satisfaction. ( Kadambande, S; Khot, S; Morgan, CL; Poole, CD, 2014) |
| "Systemic lidocaine can relieve various forms of neuropathic pain that develop after nerve injury." | 7.72 | Multiple phases of relief from experimental mechanical allodynia by systemic lidocaine: responses to early and late infusions. ( Araujo, MC; Sinnott, CJ; Strichartz, GR, 2003) |
| " Three studies are presented that provide preliminary evidence for the utility of the NPS for characterizing distinct pain qualities and changes in pain qualities in patients treated with the lidocaine patch 5% for a variety of neuropathic and non-neuropathic chronic pain conditions, including low-back pain, osteoarthritis, post-herpetic neuralgia, and painful diabetic neuropathy." | 7.72 | Introduction: chronic pain studies of the lidocaine patch 5% using the Neuropathic Pain Scale. ( Jensen, MP, 2004) |
| "Four patients with postherpetic neuralgia had their pain alleviated by epidural administration of ketamine." | 7.71 | [Usefulness of epidural administration of ketamine for relief of postherpetic neuralgia]. ( Ikeda, M; Machida, K; Mikawa, Y; Mizuno, J; Sugimoto, S, 2001) |
| "We evaluate the analgesic efficacy and safety of 9% (wt/vol) lidocaine (base) in petrolatum/paraffin ointment in patients with acute herpes zoster." | 7.69 | Treatment of the cutaneous pain of acute herpes zoster with 9% lidocaine (base) in petrolatum/paraffin ointment. ( Cork, RC; Dunston, A; Eyrich, J; Heitler, D; Johnson, W; Lopez-Anaya, A; Naraghi, M; Ragan, A; Riopelle, AJ; Riopelle, J, 1994) |
| "We report the results of a single session, non-blinded, trial of topical application of 10% lidocaine in gel form to the painful skin of 11 patients with well established post-herpetic neuralgia (PHN)." | 7.67 | Topical lidocaine reduces pain in post-herpetic neuralgia. ( Fields, HL; Rowbotham, MC, 1989) |
| "Persistent postsurgical pain is defined as pain localized to the area of surgery of a duration of ≥2 months and is, unfortunately, a common complication after breast cancer surgery." | 6.90 | Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial. ( Avram, R; Buckley, DN; Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Gilron, I; Hodgson, N; Holloway, C; Hong, NJL; Katz, J; Khan, JS; Mackey, S; McGillion, M; Paul, JE; Pohl, K; Rao-Melacini, P; Reid, S, 2019) |
| "Treatment of chronic pain conditions is commonly assessed at specific endpoints at preset times during or after treatment by analysis of the total study population." | 6.78 | A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. ( Dahan, A; Krebs-Brown, A; Martini, CH; Olofsen, E; Passier, P; Stoker, M; Yassen, A, 2013) |
| "Lidocaine tape (Penles) is a 15 cm2 dressing tape based on 60% lidocaine used to anesthetize skin when an intravenous catheter is inserted." | 6.69 | [Lidocaine tape (Penles--a dressing tape based on 60% lidocaine--) reduces the pain of postherpetic neuralgia]. ( Ogawa, H; Tamakawa, S, 1998) |
| "Lidocaine patches were superior to both no-treatment observation and vehicle patches in averaged category pain relief scores." | 6.68 | Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. ( Davies, PS; Galer, BS; Rowbotham, MC; Verkempinck, C, 1996) |
| "Lidocaine attenuates neuropathic pain and neuroinflammation by inhibiting HMGB1 to regulate the MIP-1α/CCR1/CCR5 pathway." | 5.62 | Lidocaine Alleviates Neuropathic Pain and Neuroinflammation by Inhibiting HMGB1 Expression to Mediate MIP-1α/CCR1 Pathway. ( Gu, J; Gu, K; Jiang, H; Li, C; Li, M; Sun, X; Wang, G, 2021) |
| "Herpes zoster is often associated to acute neuralgia and postherpetic neuralgia (PHN)." | 5.62 | Effectiveness and safety of lidocaine patch 5% to treat herpes zoster acute neuralgia and to prevent postherpetic neuralgia. ( Bianchi, L; Gori, F; Hansel, K; Marietti, R; Piergiovanni, C; Renzini, M; Stingeni, L; Tramontana, M, 2021) |
| "DSA-guided nerve pulse radiofrequency surgery combined with intravenous lidocaine infusion can effectively relieve pain in patients diagnosed with herpes zoster nerves at the subacute stage, reduce the number of analgesic drugs used in patients, reduce postherpetic neuralgia incidence rate, and improve sleep and quality of life." | 5.51 | Clinical Efficacy of Pulsed Radiofrequency Combined with Intravenous Lidocaine Infusion in the Treatment of Subacute Herpes Zoster Neuralgia. ( He, C; Zhang, W, 2022) |
| "Trigeminal neuralgia (TN) is a neuropathic pain condition affecting one or more branches of the trigeminal nerve." | 5.40 | Effect of 5% lidocaine medicated plaster on pain intensity and paroxysms in classical trigeminal neuralgia. ( Brugnoli, MP; Magrinelli, F; Polati, E; Schweiger, V; Tamburin, S; Zanette, G, 2014) |
| " We compared the efficacy and safety of lidocaine infusions (3 mg/kg) in the LIT group and normal saline infusions in the control group once a week for 4 consecutive weeks in patients with postherpetic neuralgia or complex regional pain syndrome type II." | 5.27 | Efficacy and Safety of Lidocaine Infusion Treatment for Neuropathic Pain: A Randomized, Double-Blind, and Placebo-Controlled Study. ( Castañeda, AM; Jin, HS; Kim, YC; Lee, CS; Moon, JY; Park, KS, 2018) |
| "This qualitative review found insufficient, heterogenous evidence and therefore no recommendation can be made for lidocaine infusion treatment in patients with chronic neuropathic pain due to spinal cord injury, peripheral nerve injury, diabetic neuropathy, postherpetic neuralgia, or complex regional pain syndrome type II." | 5.22 | Intravenous Lidocaine in Chronic Neuropathic Pain: A Systematic Review. ( Argoff, CE; Bhullar, RK; Koutalianos, EP; Lee, JH; Leimer, EM, 2022) |
| "The present study was designed to explore the efficacy of locally injected thiamine or cobalamin in relieving itch or pain and improving the daily living activities among patients with herpetic itching." | 5.19 | Thiamine, cobalamin, locally injected alone or combination for herpetic itching: a single-center randomized controlled trial. ( Lv, ZW; Tang, WZ; Xu, G; Xu, GX, 2014) |
| "A randomized, double-blind, three-period cross-over study was performed to characterize the sensory phenotype and pain demographics in patients with Morton neuroma (n=27) and to explore the effects of local administration (2mL) of placebo and lidocaine (1 and 10mg/mL) around the neuroma." | 5.17 | A pain model with a neuropathic somatosensory lesion: Morton neuroma. ( Åkermark, C; Jonzon, B; Quiding, H; Reinholdsson, I; Segerdahl, M; Svensson, H, 2013) |
| "The aim of this research is to analyze analgesic efficacy of the 5% lidocaine medicated plaster in two randomized, double-blinded, placebo-controlled, crossover studies in 16 healthy volunteers using capsaicin and sunburn pain models." | 5.15 | Antihyperalgesic efficacy of 5% lidocaine medicated plaster in capsaicin and sunburn pain models--two randomized, double-blinded, placebo-controlled crossover trials in healthy volunteers. ( Draxler, J; Gustorff, B; Hauer, D; Seis, A; Thaler, J, 2011) |
| " In this study, we evaluated the AMPA/GluR5 receptor antagonist NS1209 for efficacy, safety, and tolerability in comparison with placebo and lidocaine for the treatment of chronic neuropathic pain and allodynia in patients with peripheral nerve injury." | 5.14 | The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. ( Almqvist, PM; Finnerup, NB; Gormsen, L; Jensen, TS, 2009) |
| "Twenty patients with localized neuropathic pain [postoperative neuropathic pain (n = 14); complex regional pain syndrome (n = 2); and postherpetic neuralgia (n = 4)], who had been successfully treated with 5% lidocaine medicated plaster, were followed up by telephone interview after 3 and 5 years." | 5.14 | Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster. ( Griessinger, N; Likar, R; Sittl, R; Tzabazis, A; Wilhelm, IR, 2010) |
| "Topical lidocaine patches (LP) reduce pain in postherpetic neuralgia and other forms of focal neuropathy." | 5.14 | [Lidocaine patch for therapy of neuropathic and non-neuropathic pain. A clinical case series of 87 patients]. ( Kern, KU; Kiefer, RT; Kohl, M, 2010) |
| "To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing." | 5.11 | Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004) |
| "To determine the impact of the lidocaine patch 5% on pain qualities associated with chronic pain from postherpetic neuralgia (PHN), painful diabetic neuropathy (DN), and low-back pain (LBP), using the Neuropathic Pain Scale (NPS)." | 5.11 | Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. ( Argoff, CE; Galer, BS; Gammaitoni, AR; Jensen, MP; Oleka, N, 2004) |
| " We examined the utility of the Neuropathic Pain Scale (NPS) for assessing changes in pain qualities after open label lidocaine patch 5% in 3 samples of patients: patients with peripheral neuropathic pain, low back pain, and osteoarthritis." | 5.11 | Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale. ( Dworkin, RH; Galer, BS; Gammaitoni, AR; Jensen, MP; Olaleye, DO; Oleka, N, 2005) |
| "Topical lidocaine is effective in postherpetic neuralgia (PHN)." | 5.11 | Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. ( Baron, R; Binder, A; Kleinert, A; Schattschneider, J; Wasner, G, 2005) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 5.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Topical lidocaine has been recently marketed as a new treatment for post-herpetic neuralgia." | 5.10 | Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. ( Benowitz, NL; Campbell, BJ; Davies, PS; Jacob, P; Rowbotham, M, 2002) |
| "This study compared the efficacy of topical lidocaine patches versus vehicle (placebo) patches applied directly to the painful skin of subjects with postherpetic neuralgia (PHN) utilizing an 'enriched enrollment' study design." | 5.09 | Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. ( Friedman, E; Galer, BS; Perander, J; Rowbotham, MC, 1999) |
| "This study investigated the effect of intravenous lidocaine at two doses (1 mg/kg and 5 mg/kg over 2 hours) and an intravenous saline placebo on the pain and allodynia of postherpetic neuralgia (PHN)." | 5.09 | A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. ( Baranowski, AP; Bonello, E; De Courcey, J, 1999) |
| "A double-blind comparative clinical trial was performed with topical aspirin versus lidocaine for the treatment of 40 patients with postherpetic neuralgia." | 5.09 | Topical acetylsalicylic acid versus lidocaine for postherpetic neuralgia: results of a double-blind comparative clinical trial. ( Szok, D; Tajti, J; Vécsei, L, 1999) |
| "There was minimal change in the degree of pain in the lidocaine-only and control groups during and after the treatment period." | 5.09 | Intrathecal methylprednisolone for intractable postherpetic neuralgia. ( Asai, M; Hashimoto, H; Kimura, F; Kotani, N; Kushikata, T; Matsuki, A; Muraoka, M; Yodono, M, 2000) |
| "Analgesic efficacy of repeated application of a lidocaine cream formula was investigated in herpes zoster patients with subacute pain with no further improvement after continued treatment since their acute stage (S-HZ group, n = 23), and in patients to whom past treatments had not provided adequate pain relief (PHN group, n = 28)." | 5.09 | [Relief of subacute herpetic pain and postherpetic neuralgia with repeated application of 10% lidocaine cream]. ( Iseki, M; Mitsuhata, H; Miyazaki, T; Toriumi, E; Yoshino, K, 2000) |
| "We studied the analgesic efficacy of an intravenous infusion of lidocaine and morphine in 19 adults with well-established postherpetic neuralgia in a three-session, randomized, double-blind, placebo-controlled trial." | 5.07 | Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. ( Fields, HL; Reisner-Keller, LA; Rowbotham, MC, 1991) |
| "Clinical trials have found 5% lidocaine patches to be effective and well tolerated for the treatment of post-herpetic neuralgia (PHN) with a minimal risk of toxicity or drug-drug interactions." | 5.05 | Utility of lidocaine as a topical analgesic and improvements in patch delivery systems. ( Gudin, J; Nalamachu, S, 2020) |
| " Intravenous (iv) lidocaine is beneficial in acute and chronic pain." | 4.93 | The in vitro mechanisms and in vivo efficacy of intravenous lidocaine on the neuroinflammatory response in acute and chronic pain. ( Radema, SA; Scheffer, GJ; Steegers, MA; van Berkum, BF; van den Heuvel, SA; van der Wal, SE; Vaneker, M; Vissers, KC, 2016) |
| " In patients with neuropathic pain, topical forms of both capsaicin and lidocaine have been shown to be useful in the treatment of postherpetic neuralgia and diabetic peripheral neuropathic pain." | 4.89 | Topical therapies in the management of chronic pain. ( Galluzzi, KE; Stanos, SP, 2013) |
| " Lidocaine patches reduce neuropathic pain in postherpetic neuralgia, but their benefits for cancer-related neuropathic pain remain unclear." | 4.31 | Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment. ( Chen, YY; Chiu, GL; Huang, YT; Lai, WS; Lin, PC; Liu, IT; Su, PF; Tsai, JH, 2023) |
| " With more and more perianesthesia nurses involved with chronic pain management, it is imperative they understand the special nursing care needs of patients receiving intravenous lidocaine infusion therapy." | 4.12 | Nursing Care During Lidocaine Infusion Therapy for Chronic Pain. ( Wren, KR, 2022) |
| " LCipsi inactivation with lidocaine increased cold allodynia 2 days after nerve injury but not later." | 4.12 | Nerve injury induces transient locus coeruleus activation over time: role of the locus coeruleus-dorsal reticular nucleus pathway. ( Berrocoso, E; Bravo, L; Camarena-Delgado, C; Garcia-Partida, JA; Llorca-Torralba, M; López-Martín, C; Mico, JA; Suárez-Pereira, I, 2022) |
| "Based on clinical study results, 5% lidocaine-medicated plaster (5% LMP) is currently recommended for the treatment of localized peripheral neuropathic pain, such as post-herpetic neuralgia (PHN)." | 3.85 | Efficacy and safety of 5% lidocaine-medicated plasters in localized pain with neuropathic and/or inflammatory characteristics: an observational, real-world study. ( Amato, F; Ciliberto, G; Consoletti, L; Duse, G; Firetto, V; Lo Presti, C; Mazza, M; Palmieri, V; Parigi, LA, 2017) |
| "5% lidocaine medicated plasters are a topical option in the treatment of peripheral neuropathic pain, as monotherapy or as an adjunct to systemic medication." | 3.80 | Use of 5% lidocaine medicated plasters for the treatment of pain in routine hospital practice: patient reported pain, functioning and satisfaction. ( Kadambande, S; Khot, S; Morgan, CL; Poole, CD, 2014) |
| "We assessed prescription patterns for four top-selling orphan drugs: lidocaine patch (Lidoderm) approved for post-herpetic neuralgia, modafinil (Provigil) approved for narcolepsy, cinacalcet (Sensipar) approved for hypercalcemia of parathyroid carcinoma, and imatinib (Gleevec) approved for chronic myelogenous leukemia and gastrointestinal stromal tumor." | 3.78 | The prevalence and cost of unapproved uses of top-selling orphan drugs. ( Avorn, J; Kesselheim, AS; Levin, R; Myers, JA; Solomon, DH; Winkelmayer, WC, 2012) |
| " In this chart review, the efficacy of ONB using lidocaine and dexamethasone was evaluated in 20 patients with craniofacial pain syndromes comprising 8 patients with trigeminal neuralgia, 6 with trigeminal neuropathic pain, 5 with persistent idiopathic facial pain and 1 with occipital neuralgia." | 3.78 | Occipital nerve block is effective in craniofacial neuralgias but not in idiopathic persistent facial pain. ( Jürgens, TP; May, A; Müller, P; Regelsberger, J; Seedorf, H, 2012) |
| " Stratification by diagnosis showed a treatment effect of lidocaine plaster for all underlying conditions with highest treatment effects for diabetic polyneuropathy and postherpetic neuralgia." | 3.78 | Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice. ( Müller-Schwefe, GH; Überall, MA, 2012) |
| " We concluded that only peripheral blockade of transient receptor potential vanilloid receptor 1-expressing nociceptive afferents by the QX-314/capsaicin combination was effective at reducing neuropathic allodynia and hyperalgesia." | 3.78 | Differential effects of peripheral versus central coadministration of QX-314 and capsaicin on neuropathic pain in rats. ( Cheng, J; Fox, LE; Shen, J, 2012) |
| "Systemic lidocaine can relieve various forms of neuropathic pain that develop after nerve injury." | 3.72 | Multiple phases of relief from experimental mechanical allodynia by systemic lidocaine: responses to early and late infusions. ( Araujo, MC; Sinnott, CJ; Strichartz, GR, 2003) |
| " Three studies are presented that provide preliminary evidence for the utility of the NPS for characterizing distinct pain qualities and changes in pain qualities in patients treated with the lidocaine patch 5% for a variety of neuropathic and non-neuropathic chronic pain conditions, including low-back pain, osteoarthritis, post-herpetic neuralgia, and painful diabetic neuropathy." | 3.72 | Introduction: chronic pain studies of the lidocaine patch 5% using the Neuropathic Pain Scale. ( Jensen, MP, 2004) |
| "Four patients with postherpetic neuralgia had their pain alleviated by epidural administration of ketamine." | 3.71 | [Usefulness of epidural administration of ketamine for relief of postherpetic neuralgia]. ( Ikeda, M; Machida, K; Mikawa, Y; Mizuno, J; Sugimoto, S, 2001) |
| "Lidocaine patch 5% comprises a soft, stretchy adhesive patch (l0 by 14 cm) containing 5% lidocaine (700 mg) for the topical treatment of pain associated with postherpetic neuralgia (PHN)." | 3.70 | Lidocaine patch 5%. ( Comer, AM; Lamb, HM, 2000) |
| "We evaluate the analgesic efficacy and safety of 9% (wt/vol) lidocaine (base) in petrolatum/paraffin ointment in patients with acute herpes zoster." | 3.69 | Treatment of the cutaneous pain of acute herpes zoster with 9% lidocaine (base) in petrolatum/paraffin ointment. ( Cork, RC; Dunston, A; Eyrich, J; Heitler, D; Johnson, W; Lopez-Anaya, A; Naraghi, M; Ragan, A; Riopelle, AJ; Riopelle, J, 1994) |
| "We report the results of a single session, non-blinded, trial of topical application of 10% lidocaine in gel form to the painful skin of 11 patients with well established post-herpetic neuralgia (PHN)." | 3.67 | Topical lidocaine reduces pain in post-herpetic neuralgia. ( Fields, HL; Rowbotham, MC, 1989) |
| "We conducted meta-analyses to evaluate the effect of topical lidocaine on pain intensity, adverse events, and quality of life." | 3.54 | Effect and safety profile of topical lidocaine on post-surgical neuropathic pain and quality of life: A systematic review and meta-analysis. ( Chang, Y; Fan, B; Li, Y; Liu, B; Mao, P; Zhang, Y; Zhu, M, 2024) |
| "Lidocaine administration reduced mean Neuropathic Pain Symptom Inventory paresthesia/dysesthesia scores when compared with placebo by 1." | 3.01 | Prediction of Individual Analgesic Response to Intravenous Lidocaine in Painful Diabetic Peripheral Neuropathy: A Randomized, Placebo-controlled, Crossover Trial. ( Bakos, K; Bottros, M; Frey, K; Haroutounian, S; Kagan, L; Kraus, K; Lee, JB; Meacham, K; Rao, L; Swarm, RA; Tallchief, D; Todorovic, MS; Zang, X, 2021) |
| "All of the patients exhibited neuropathic pain scored according to the Douleur Neuropathique 4 (DN4) of ≥4 for at least 6 months." | 2.90 | Effect of piriformis injection on neuropathic pain. ( Erçalık, T; Terlemez, R, 2019) |
| "Treatment with lidocaine or placebo plaster led to a clinically relevant reduction in average pain intensity." | 2.90 | Lidocaine medicated plaster, an additional potential treatment option for localized post-surgical neuropathic pain: efficacy and safety results of a randomized, placebo-controlled trial. ( Attal, N; Boesl, I; Buchheister, B; Koenig, S; Palladini, M, 2019) |
| "Persistent postsurgical pain is defined as pain localized to the area of surgery of a duration of ≥2 months and is, unfortunately, a common complication after breast cancer surgery." | 2.90 | Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial. ( Avram, R; Buckley, DN; Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Gilron, I; Hodgson, N; Holloway, C; Hong, NJL; Katz, J; Khan, JS; Mackey, S; McGillion, M; Paul, JE; Pohl, K; Rao-Melacini, P; Reid, S, 2019) |
| "From day 7 onwards, dynamic mechanical allodynia diminished progressively of ≥ 30% over 3 months (P = 0." | 2.90 | Effectiveness and safety of 5% lidocaine-medicated plaster on localized neuropathic pain after knee surgery: a randomized, double-blind controlled trial. ( Ganry, H; Macian, N; Pereira, B; Pickering, G; Voute, M, 2019) |
| "Patients with chronic neuropathic pain after primary Lichtenstein repair and >50% pain reduction after a diagnostic TPI were randomized for repeated TPI (combined Lidocaine/corticosteroids /hyaluronic acid injection) or for a neurectomy." | 2.87 | The GroinPain Trial: A Randomized Controlled Trial of Injection Therapy Versus Neurectomy for Postherniorraphy Inguinal Neuralgia. ( Loos, MJA; Roumen, RMH; Scheltinga, MRM; Verhagen, T, 2018) |
| "The management of neuropathic pain and pain related to bone vaso-occlusive crises in sickle cell disease remains challenging in children." | 2.87 | Efficacy and Tolerance of Lidocaine 5% Patches in Neuropathic Pain and Pain Related to Vaso-occlusive Sickle Cell Crises in Children: A Prospective Multicenter Clinical Study. ( Arriuberge, C; Chabaud, S; Darnis, S; Launay, V; Marec-Berard, P; Metzger, S; Morelle, M; Roumenoff-Turcant, F; Rousseau, V; Thouvenin, S; Tourniaire, B, 2018) |
| "It is a neuropathic pain condition and may mimic dental and other trigeminal pain entities." | 2.82 | Trigeminal Traumatic Neuroma: a Comprehensive Review of the Literature Based On a Rare Case. ( Mallareddy, SD; Okeson, JP; Pichammal, RC; Pitchumani, PK; Thankachan, J; Thomas, DC, 2022) |
| "Forty-six patients with neuropathic pain due to nerve injury or postherpetic neuralgia were randomised." | 2.80 | Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study. ( Demant, DT; Finnerup, NB; Jensen, TS; Lund, K; Maier, C; Segerdahl, MS; Sindrup, SH; Vollert, J, 2015) |
| "Treatment of chronic pain conditions is commonly assessed at specific endpoints at preset times during or after treatment by analysis of the total study population." | 2.78 | A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. ( Dahan, A; Krebs-Brown, A; Martini, CH; Olofsen, E; Passier, P; Stoker, M; Yassen, A, 2013) |
| "Twenty-eight cancer patients with postsurgical incisional pain were randomly assigned to receive either lidocaine patches followed by placebo patches or the reverse." | 2.74 | Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). ( Bearden Iii, JD; Cheville, AL; Christensen, BJ; Jillella, AP; Liu, H; Loprinzi, CL; Marchello, BT; Northfelt, DW; Schaefer, PL; Sloan, JA; Wong, GY, 2009) |
| "This post-operative/post-traumatic neuropathic chronic cutaneous pain (PNCCP) may be a side-effect of any incision of the skin in the context of a surgical procedure or a traumatic event." | 2.74 | Management of neuropathic pain after surgical and non-surgical trauma with lidocaine 5% patches: study of 40 consecutive cases. ( Hans, G; Joukes, E; Vercauteren, M; Verhulst, J, 2009) |
| "Lidocaine is an amino amide with a well-established role as a local anesthetic agent." | 2.72 | Lidocaine Infusions for Pain Management in Pediatrics. ( Anghelescu, DL; Davis, MS; Hall, EA; Sauer, HE, 2021) |
| "Neuropathic pain is often severe and resistant to pharmacological treatment." | 2.71 | The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. ( Emanuelsson, BM; Gordh, T; Karlsten, R; Kvarnström, A; Quiding, H, 2003) |
| "Lidocaine tape (Penles) is a 15 cm2 dressing tape based on 60% lidocaine used to anesthetize skin when an intravenous catheter is inserted." | 2.69 | [Lidocaine tape (Penles--a dressing tape based on 60% lidocaine--) reduces the pain of postherpetic neuralgia]. ( Ogawa, H; Tamakawa, S, 1998) |
| "Lidocaine 50 mg was associated with a greater decrease in systolic blood pressure and a greater need for ephedrine." | 2.69 | A comparison of minidose lidocaine-fentanyl and conventional-dose lidocaine spinal anesthesia. ( Ben-David, B; DeMeo, PJ; Frankel, R; Gurevitch, A; Lucyk, C; Maryanovsky, M; Solosko, D; Volpin, G, 2000) |
| "Lidocaine 1." | 2.68 | [The efficacy of intravenous lidocaine on various types of neuropathic pain]. ( Adachi, N; Amakawa, K; Arai, T; Fujitani, T; Inoue, H; Kimura, S; Nagaro, T; Oka, S; Shimizu, C; Watanabe, T, 1995) |
| "Lidocaine patches were superior to both no-treatment observation and vehicle patches in averaged category pain relief scores." | 2.68 | Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. ( Davies, PS; Galer, BS; Rowbotham, MC; Verkempinck, C, 1996) |
| "The prevalence of neuropathic pain in the older population has been reported to be very high and is most commonly localized to a circumscribed area." | 2.66 | Topical Treatment of Localized Neuropathic Pain in the Elderly. ( Lucchini, C; Pickering, G, 2020) |
| "The use of topiceuticals in localized neuropathic pain associated with malignancy remain a valuable option with many advantages over systemic treatments." | 2.55 | The role of topiceuticals in cancer pain. ( Paisley, P; Serpell, M, 2017) |
| "Indomethacin is the best treatment both for HC and PH." | 2.55 | Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. ( Baraldi, C; Cainazzo, MM; Guerzoni, S; Pellesi, L; Pini, LA, 2017) |
| "Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy." | 2.55 | Neuropathic pain. ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| "Localized neuropathic pain (LNP) is a type of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain, which are associated with negative or positive sensory signs and/or spontaneous symptoms typical of neuropathic pain." | 2.50 | [Localized neuropathic pain--5% lidocaine medicated patch as a first-line treatment and as add-on therapy: literature review and personal experience]. ( Bhaskar, A; Casale, R; Coluzzi, F; Consalvo, M; Polati, E; Schweiger, V, 2014) |
| "Lidocaine is a local anaesthetic that is sometimes used on the skin to treat neuropathic pain." | 2.50 | Topical lidocaine for neuropathic pain in adults. ( Derry, S; Moore, RA; Quinlan, J; Wiffen, PJ, 2014) |
| "Understanding mechanisms of neuropathic orofacial pain, targets of treatment, and basic pharmacology and working with informed compounding pharmacists may result in significant benefit for patients." | 2.49 | Topical medications as treatment of neuropathic orofacial pain. ( Heir, GM; Khan, J; Nasri-Heir, C, 2013) |
| "As in neuropathic pain, decreased brain activation to heat stimuli has been demonstrated with fMRI in BMS patients." | 2.48 | Pathophysiology of primary burning mouth syndrome. ( Jääskeläinen, SK, 2012) |
| "A 37-year-old woman with progressive facial hemiatrophy and strictly left-sided facial pain over 12 years." | 2.47 | Trigeminal neuropathic pain in a patient with progressive facial hemiatrophy (parry-romberg syndrome). ( Glastonbury, CM; Goadsby, PJ; Sprenger, T; Viana, M, 2011) |
| "A number of different treatments for neuropathic pain have been studied, but the literature is sizable, rapidly evolving, and lacks important information about practical aspects of patient management." | 2.45 | Treatment of neuropathic pain: an overview of recent guidelines. ( Dworkin, RH; O'Connor, AB, 2009) |
| "Some mechanisms of the development of neuropathic pain have been proposed; 1) sprouting of A beta fibers to the superficial layer of the dorsal horn, 2) ectopic discharge in the dorsal root ganglion and/or in neuroma at the nerve stump, 3) spinal sensitization." | 2.44 | [Mechanisms of the development of neuropathic pain and its treatment]. ( Yamamoto, T, 2008) |
| "Managing patients with chronic neuropathic pain is a common clinical challenge due to variability in individual symptoms, mechanisms, and treatment responses." | 2.42 | Diagnosis and management of neuropathic pain: a balanced approach to treatment. ( Nicholson, BD, 2003) |
| "Neuropathic pain has long been recognised as one of the more difficult types of pain to treat; however, with the current emphasis on providing a multidisciplinary assessment and approach to management, more patients will be offered relief of their symptoms and an improved quality of life." | 2.41 | Management strategies for the treatment of neuropathic pain in the elderly. ( Ahmad, M; Goucke, CR, 2002) |
| "Mechanisms of neuropathic pain relief from lidocaine therapy are yet to be understood." | 2.41 | Systemic lidocaine for neuropathic pain relief. ( Chen, LL; Mao, J, 2000) |
| "Neuropathic pain is frequently associated with hyperexcitability of primary afferents, characterized by spontaneous impulses and repetitive firing." | 2.41 | Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain. ( Khodorova, A; Sinnott, C; Strichartz, GR; Zhou, Z, 2002) |
| "Management of persistent idiopathic facial pain (PIFP) can be challenging." | 1.91 | Effect of neuropathic pain on sphenopalatine ganglion block responses in persistent idiopathic facial pain. ( Akçaboy, EY; Çelik, Ş; Göksu, H; Kaya, SS; Şahin, Ş; Yıldız, G, 2023) |
| "Lidocaine plaster treatment resulted in superior pain relief, significantly fewer restrictions in daily life activities and better quality of life than the oral medications evaluated and was significantly better tolerated." | 1.72 | Localized peripheral neuropathic pain: topical treatment with lidocaine 700 mg medicated plaster in routine clinical practice. ( Bösl, I; Eerdekens, M; Hollanders, E; Sabatschus, I; Überall, MA, 2022) |
| "The results showed that CCI-ION induced hyperalgesia, which was attenuated by lidocaine or carbamazepine, developed anxiety-like behavior, which was reduced only by midazolam, and displayed a reduced number of 50-kHz calls, compared to sham." | 1.72 | Trigeminal neuropathic pain reduces 50-kHz ultrasonic vocalizations in rats, which are restored by analgesic drugs. ( Araya, EI; Baggio, DF; Chichorro, JG; Koren, LO; Schwarting, RKW, 2022) |
| "Neuropathic orofacial pain disorders are frequently managed with topical or systemic medications that carry a risk of dangerous side effects such as drowsiness, disorientation, and/or physical addiction." | 1.72 | Oral appliances in the management of neuropathic orofacial pain: A retrospective case series. ( Bavarian, R; Khawaja, SN; Treister, NS, 2022) |
| "Lidocaine attenuates neuropathic pain and neuroinflammation by inhibiting HMGB1 to regulate the MIP-1α/CCR1/CCR5 pathway." | 1.62 | Lidocaine Alleviates Neuropathic Pain and Neuroinflammation by Inhibiting HMGB1 Expression to Mediate MIP-1α/CCR1 Pathway. ( Gu, J; Gu, K; Jiang, H; Li, C; Li, M; Sun, X; Wang, G, 2021) |
| "Herpes zoster is often associated to acute neuralgia and postherpetic neuralgia (PHN)." | 1.62 | Effectiveness and safety of lidocaine patch 5% to treat herpes zoster acute neuralgia and to prevent postherpetic neuralgia. ( Bianchi, L; Gori, F; Hansel, K; Marietti, R; Piergiovanni, C; Renzini, M; Stingeni, L; Tramontana, M, 2021) |
| "Lidocaine is a commonly used drug to alleviate neuropathic pain (NP)." | 1.62 | Lidocaine activates autophagy of astrocytes and ameliorates chronic constriction injury-induced neuropathic pain. ( Fei, Y; Yuan, J, 2021) |
| "Lidocaine levels were performed in 3 patients but did not change management." | 1.62 | Lidocaine Continuous Subcutaneous Infusion for Neuropathic Pain in Hospice Patients: Safety and Efficacy. ( Hunt, RW; Kiani, CS, 2021) |
| "Neuropathic pain is frequently driven by ectopic impulse discharge (ectopia) generated in injured peripheral afferent neurons." | 1.51 | Suppression of neuropathic pain by selective silencing of dorsal root ganglion ectopia using nonblocking concentrations of lidocaine. ( Devor, M; Yatziv, SL, 2019) |
| "Patients with neuropathic pain are highly motivated for pain relief, and as motivational factors such as expectations of reward, as well as pain processing in itself, are related to the dopaminergic system, it can be speculated that dopamine release contributes to placebo effects in neuropathic pain." | 1.48 | Dopaminergic tone does not influence pain levels during placebo interventions in patients with chronic neuropathic pain. ( Baastrup, C; Benedetti, F; Grosen, K; Hall, KT; Jensen, TS; Kaptchuk, TJ; Moslemi, K; Petersen, GL; Price, DD; Skyt, I; Svensson, P; Vase, L, 2018) |
| "The study included 19 patients with neuropathic pain." | 1.48 | Does conditioned pain modulation predict the magnitude of placebo effects in patients with neuropathic pain? ( Baastrup, C; Grosen, K; Jensen, TS; Moslemi, K; Skyt, I; Svensson, P; Vase, L, 2018) |
| "Primary hyperalgesia was characterized by pronounced gain for heat, pressure and pinprick pain, and mild thermal sensory loss." | 1.48 | Pathophysiological mechanisms of neuropathic pain: comparison of sensory phenotypes in patients and human surrogate pain models. ( Baron, R; Binder, A; Enax-Krumova, EK; Geisslinger, G; Gierthmühlen, J; Henrich, F; Hüllemann, P; Klein, T; Lötsch, J; Magerl, W; Maier, C; Oertel, B; Schuh-Hofer, S; Tölle, TR; Treede, RD; Vollert, J, 2018) |
| "The effect of AMN082 on mechanical allodynia and glutamate release was blocked by 6-(2,4-dimethylphenyl)-2-ethyl-6,7-dihydro-4(5H)-benzoxazolone (ADX71743), a selective mGluR7 negative allosteric modulator." | 1.48 | Metabotropic glutamate receptor subtype 7 in the dorsal striatum oppositely modulates pain in sham and neuropathic rats. ( Boccella, S; de Novellis, V; Farina, A; Guida, F; Iannotta, M; Luongo, L; Maione, S; Marabese, I; Palazzo, E; Serra, N, 2018) |
| "Central poststroke pain (CPSP) is a neuropathic pain disorder, the underlying mechanisms of which are not well understood." | 1.48 | How central is central poststroke pain? The role of afferent input in poststroke neuropathic pain: a prospective, open-label pilot study. ( Bottros, MM; Finnerup, NB; Ford, AL; Frey, K; Haroutounian, S; Karlsson, P; Kharasch, ED; Neiner, A; Nikolajsen, L, 2018) |
| "Localized neuropathic pain (LNP) is a subgroup of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain, associated with negative or positive sensory signs and/or spontaneous symptoms characteristic of NP." | 1.48 | Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy. ( Chinellato, E; Del Balzo, G; Martini, A; Parolini, M; Picelli, A; Polati, E; Schweiger, V; Tamburin, S; Zanzotti, M, 2018) |
| "In patients with focal nerve injury and neuropathic pain cutting the nerve to obtain permanent pain reduction can be considered." | 1.48 | Predictive value of a diagnostic block in focal nerve injury with neuropathic pain when surgery is considered. ( Dahan, A; de Boer, R; Eekhof, JLA; Kliot, M; Malessy, MJA; Muñoz Romero, I; Pondaag, W; van Zwet, EW, 2018) |
| " Patients' demographic and clinical characteristics, resource utilization data and adverse drug reactions (ADRs) as described in the leaflet were extracted." | 1.46 | Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe - the role of the lidocaine 5% medicated plaster. ( Katz, P; Liedgens, H; Pegoraro, V, 2017) |
| "Myocardial infarction is the leading cause of death worldwide." | 1.46 | Cardioprotection induced in a mouse model of neuropathic pain via anterior nucleus of paraventricular thalamus. ( Chang, YT; Chen, CC; Chen, WH; Chen, YH; Cheng, YF; Shih, HC; Shyu, BC, 2017) |
| "Neuropathic pain is a common and distressing symptom in thoracic surgical patients." | 1.46 | Lidocaine 5% medicated plaster for localized neuropathic pain in thoracic surgical patients. ( Ambrosio, F; Freo, U; Ori, C, 2017) |
| "Neuropathic pain is caused by a lesion or disease affecting the somatosensory system and is difficult to manage, often proving refractory to existing treatments." | 1.43 | A pharmacological treatment algorithm for localized neuropathic pain. ( Allegri, M; Baron, R; Correa-Illanes, G; Hans, G; Mayoral Rojals, V; Mick, G; Serpell, M, 2016) |
| "The lidocaine topical treatment was continued for months with durable analgesic effect." | 1.43 | Lidocaine 5% Medicated Plaster for Spinal Neuropathic Pain. ( Ambrosio, F; Freo, U; Furnari, M; Ori, C, 2016) |
| "Pharmacotherapy of neuropathic pain involves the use of antiepileptic agents, antidepressants, and opioids that may lead to numerous adverse effects, particularly in elderly patients." | 1.43 | Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients. ( Dobrogowski, J; Kocot-Kępska, M; Mika, J; Przeklasa-Muszyńska, A; Wiatr, M, 2016) |
| "• Occipital neuralgia is a very painful and debilitating condition • GON infiltrations have been successful in the treatment of occipital neuralgia • This simplified technique presents a high efficacy rate with long-lasting pain relief • This infiltration technique does not require contrast media injection for pre-planning • GON infiltration at the first bend appears easier and safer." | 1.42 | A simplified CT-guided approach for greater occipital nerve infiltration in the management of occipital neuralgia. ( Attyé, A; Comte, A; Kastler, A; Kastler, B; Lajoie, JL; Onana, Y, 2015) |
| "The management of patients with neuropathic pain is challenging." | 1.42 | Prolonged Suppression of Neuropathic Pain by Sequential Delivery of Lidocaine and Thalidomide Drugs Using PEGylated Graphene Oxide. ( Gu, K; Guan, J; Ma, P; Ma, X; Qi, Y; Song, T; Wang, C; Wang, H; Wang, W; Ya, J; Yan, R; Yang, L; Yang, Y; Zhao, J, 2015) |
| "Mechanical allodynia, induced by normally innocuous low-threshold mechanical stimulation, represents a cardinal feature of neuropathic pain." | 1.42 | Inhibition of mechanical allodynia in neuropathic pain by TLR5-mediated A-fiber blockade. ( Bang, S; Berta, T; Ji, RR; Kim, YH; Oh, SB; Wang, F; Xu, ZZ; Zhang, Y, 2015) |
| "Ambroxol acts as a strong local anesthetic and preferentially inhibits the nociceptive-relevant sodium channel subtype Nav 1." | 1.42 | [Topical ambroxol for the treatment of neuropathic pain: A first clinical observation. German version]. ( Kern, KU; Weiser, T, 2015) |
| "Osteoarthritis is the most common form of arthritis and includes manifestations of both nociceptive and neuropathic mechanisms." | 1.40 | Osteoarthritis pain has a significant neuropathic component: an exploratory in vivo patient model. ( Ashford, RL; Dimitroulas, T; Duarte, RV; Kitas, GD; Raphael, JH; Southall, JL; Sparkes, E, 2014) |
| "Lidocaine pretreatment does not have a significant effect on tolerability, efficacy, or patient willingness to receive retreatment." | 1.40 | Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary? ( Kern, KU; Nowack, W; Poole, C, 2014) |
| "Fourteen patients with neuropathic pain (7 with unilateral foot pain due to peripheral nerve injury and 7 with bilateral pain in the feet due to distal polyneuropathy) underwent comprehensive characterization of somatosensory function by quantitative sensory testing." | 1.40 | Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy. ( Bendtsen, TF; Finnerup, NB; Haroutounian, S; Hasselstrøm, JB; Jensen, TS; Kristensen, AD; Nikolajsen, L, 2014) |
| "Trigeminal neuralgia (TN) is a neuropathic pain condition affecting one or more branches of the trigeminal nerve." | 1.40 | Effect of 5% lidocaine medicated plaster on pain intensity and paroxysms in classical trigeminal neuralgia. ( Brugnoli, MP; Magrinelli, F; Polati, E; Schweiger, V; Tamburin, S; Zanette, G, 2014) |
| "Eighteen patients with postthoracotomy neuropathic pain were exposed to placebo and nocebo manipulations, in which they received open and hidden administrations of pain-relieving (lidocaine) or pain-inducing (capsaicin) treatment controlled for the natural history of pain." | 1.40 | Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions. ( Benedetti, F; Finnerup, NB; Grosen, K; Jensen, TS; Petersen, GL; Pilegaard, HK; Price, DD; Tracey, I; Vase, L, 2014) |
| "The treatment of neuropathic pain is a medical challenge." | 1.40 | [Topical pharmacologic approach with 5% lidocaine medicated plaster in the treatment of localized neuropathic pain]. ( Chiarlone, R; Fogliardi, A; Intelligente, F; Irace, C; Lanzilotta, M; Lattanzi, S; Palomba, R; Provinciali, L; Storelli, E; Zampi, M, 2014) |
| "Mechanisms underlying the chronicity of neuropathic pain are not well understood." | 1.39 | Descending facilitation maintains long-term spontaneous neuropathic pain. ( De Felice, M; Guo, W; King, T; Ossipov, MH; Porreca, F; Wang, R, 2013) |
| "Levobupivacaine was more potent than lidocaine in all tests employed on diabetic rats." | 1.39 | Comparison of actions of systemically and locally administrated local anaesthetics in diabetic rats with painful neuropathy. ( Gunay, I; Gunes, Y; Mert, T, 2013) |
| "Neuropathic pain is a challenge in children with burn sequelae." | 1.39 | 5% lidocaine medicated plaster use in children with neuropathic pain from burn sequelae. ( Hidalgo, G; Orellana Silva, M; Saavedra, R; Valenzuela, F; Yañez, V, 2013) |
| "The University of Washington Neuropathic Pain Scale was used to grade the neuropathic pain before and after use of the interventional gel." | 1.38 | Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: a pilot study. ( Gerbis, B; Gillis, D; Holwerda, E; Uzaraga, I; Wai, E, 2012) |
| "This syndrome is usually related to anatomic variants (involving the bone structures, fibrous bands, or muscles and tendons)." | 1.38 | Supraclavicular nerve entrapment syndrome. ( Bruyère, PJ; Courtois, AC; Crielaard, JM; Douchamps, F, 2012) |
| "For difficult to treat neuropathic pain from cancer, adjuvant analgesics are often used with opioids." | 1.38 | Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain. ( Kajiume, T; Karakawa, S; Kawaguchi, H; Kobayakawa, M; Kobayashi, M; Nakanuno, R; Ogura, T; Oshita, K; Sato, T; Sera, Y; Taguchi, S, 2012) |
| "Neuropathic pain was assessed based on behavioral responses to thermal and mechanical stimuli." | 1.37 | Intrathecal lidocaine pretreatment attenuates immediate neuropathic pain by modulating Nav1.3 expression and decreasing spinal microglial activation. ( Chang, LL; Cheng, KI; Ho, ST; Kwan, AL; Lai, CS; Tsai, HP; Wang, FY; Wang, HC, 2011) |
| "The term "peripheral neuropathic pain syndromes" summarizes several chronic pain syndromes, which can occur focally or generalized in the peripheral nervous system in the course of an impairment of afferent neurons." | 1.36 | [Types of topical treatment for peripheral neuropathic pain : Mechanism of action and indications]. ( Baron, R; Mahn, F, 2010) |
| "5% Lidocaine patches have been used for treatment of chronic neuropathic pain in adults and we have found this to be effective in management of localized neuropathic pain in children and adolescents." | 1.35 | Lidocaine 5% patch for localized chronic neuropathic pain in adolescents: report of five cases. ( Cunliffe, M; Nayak, S, 2008) |
| "Lidocaine was soaked on spinal nerves or intrathecally injected 10 min before SNT to block neuronal discharges caused by the injury, and L703,606 (NK1 receptor antagonist) and CGRP8-37 (CGRP receptor antagonist) were intrathecally injected into the rats to block actions of substance P and CGRP released from central nerve terminals in the spinal cord by injury discharges." | 1.34 | Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat. ( Kim, JH; Lee, SE, 2007) |
| "The pathophysiology of many types of chronic headaches is not well understood." | 1.33 | Cervicogenic headache in patients with presumed migraine: missed diagnosis or misdiagnosis? ( Cook, AJ; Hamill-Ruth, RJ; Rowlingson, JC; Yi, X, 2005) |
| "Predictors of response to neuropathic pain treatment in patients with painful distal sensory neuropathies are lacking." | 1.33 | Skin biopsy and quantitative sensory testing do not predict response to lidocaine patch in painful neuropathies. ( Barbano, RL; Dworkin, RH; Herrmann, DN; Pannoni, V; Pennella-Vaughan, J, 2006) |
| "His headaches fit the IHS criteria for cluster headache but had some irregularities including frequent side shifting of pain, irregular duration and time of onset and the ability of the patient to sit completely still during a headache without any sense of agitation." | 1.33 | Non-hypothalamic cluster headache: the role of the greater occipital nerve in cluster headache pathogenesis. ( Rozen, TD, 2005) |
| "Evidence suggests that some neuropathic pain behaviors are closely associated with extensive sprouting of noradrenergic sympathetic fibers in the dorsal root ganglia (DRG)." | 1.32 | Decreasing sympathetic sprouting in pathologic sensory ganglia: a new mechanism for treating neuropathic pain using lidocaine. ( Li, H; Munir, MA; Zhang, JM, 2004) |
| "The management of patients with neuropathic pain is challenging." | 1.30 | The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. ( Abdi, S; Chung, JM; Lee, DH, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (9.67) | 18.7374 |
| 1990's | 31 (11.52) | 18.2507 |
| 2000's | 72 (26.77) | 29.6817 |
| 2010's | 106 (39.41) | 24.3611 |
| 2020's | 34 (12.64) | 2.80 |
| Authors | Studies |
|---|---|
| Todorovic, MS | 1 |
| Frey, K | 2 |
| Swarm, RA | 1 |
| Bottros, M | 1 |
| Rao, L | 1 |
| Tallchief, D | 1 |
| Kraus, K | 1 |
| Meacham, K | 1 |
| Bakos, K | 1 |
| Zang, X | 1 |
| Lee, JB | 1 |
| Kagan, L | 1 |
| Haroutounian, S | 3 |
| Fallico, N | 1 |
| Padmanabhan, R | 1 |
| Rahman, S | 1 |
| Somma, F | 1 |
| Spagnoli, AM | 1 |
| Wren, KR | 1 |
| Überall, MA | 2 |
| Bösl, I | 2 |
| Hollanders, E | 2 |
| Sabatschus, I | 2 |
| Eerdekens, M | 2 |
| Camarena-Delgado, C | 1 |
| Llorca-Torralba, M | 1 |
| Suárez-Pereira, I | 1 |
| Bravo, L | 1 |
| López-Martín, C | 1 |
| Garcia-Partida, JA | 1 |
| Mico, JA | 1 |
| Berrocoso, E | 1 |
| Thomas, DC | 1 |
| Mallareddy, SD | 1 |
| Okeson, JP | 1 |
| Thankachan, J | 1 |
| Pitchumani, PK | 1 |
| Pichammal, RC | 1 |
| Araya, EI | 1 |
| Baggio, DF | 1 |
| Koren, LO | 1 |
| Schwarting, RKW | 1 |
| Chichorro, JG | 1 |
| Featherly, J | 1 |
| Baxter Wojnowicz, S | 1 |
| Steidl, K | 1 |
| Burgess, J | 1 |
| Zhang, W | 1 |
| He, C | 1 |
| A Überall, M | 1 |
| Landmann, G | 1 |
| Stockinger, L | 1 |
| Gerber, B | 1 |
| Benrath, J | 1 |
| Schmelz, M | 1 |
| Rukwied, R | 1 |
| Lee, JH | 1 |
| Koutalianos, EP | 1 |
| Leimer, EM | 1 |
| Bhullar, RK | 1 |
| Argoff, CE | 4 |
| Li, J | 1 |
| Huang, Y | 1 |
| Lin, J | 1 |
| Kaya, SS | 3 |
| Çelik, Ş | 3 |
| Akçaboy, EY | 3 |
| Göksu, H | 3 |
| Yıldız, G | 3 |
| Şahin, Ş | 3 |
| Tsai, JH | 1 |
| Liu, IT | 1 |
| Su, PF | 1 |
| Huang, YT | 1 |
| Chiu, GL | 1 |
| Chen, YY | 1 |
| Lai, WS | 1 |
| Lin, PC | 1 |
| Lee, J | 1 |
| Currow, D | 1 |
| Lovell, M | 1 |
| Phillips, JL | 1 |
| McLachlan, A | 1 |
| Ritchie, M | 1 |
| Brown, L | 1 |
| Fazekas, B | 1 |
| Aggarwal, R | 1 |
| Seah, D | 1 |
| Sheehan, C | 1 |
| Chye, R | 1 |
| Noble, B | 1 |
| McCaffrey, N | 1 |
| Aggarwal, G | 1 |
| George, R | 1 |
| Kow, M | 1 |
| Ayoub, C | 1 |
| Linton, A | 1 |
| Sanderson, C | 1 |
| Mittal, D | 1 |
| Rao, A | 1 |
| Prael, G | 1 |
| Urban, K | 1 |
| Vandersman, P | 1 |
| Agar, M | 1 |
| Hans, GH | 2 |
| Almeshal, D | 1 |
| Vanlommel, L | 1 |
| Roelant, E | 1 |
| Verhaegen, I | 1 |
| Smits, E | 1 |
| Van Boxem, K | 1 |
| Fontaine, R | 1 |
| Investigators Team, TP | 1 |
| Mao, P | 1 |
| Zhang, Y | 3 |
| Liu, B | 1 |
| Li, Y | 1 |
| Chang, Y | 1 |
| Zhu, M | 1 |
| Fan, B | 1 |
| Kaisler, M | 1 |
| Maier, C | 3 |
| Kumowski, N | 1 |
| Schwarzer, A | 1 |
| Meyer-Frießem, CH | 1 |
| Terlemez, R | 1 |
| Erçalık, T | 1 |
| Gudin, J | 1 |
| Nalamachu, S | 2 |
| Pickering, G | 3 |
| Lucchini, C | 1 |
| Cohrs, J | 1 |
| Kerns, R | 1 |
| Li, M | 1 |
| Jiang, H | 1 |
| Gu, K | 2 |
| Sun, X | 1 |
| Gu, J | 1 |
| Li, C | 1 |
| Wang, G | 1 |
| Silvinato, A | 2 |
| Floriano, I | 2 |
| Bernardo, WM | 2 |
| Iolascon, G | 1 |
| Kocatürk, M | 1 |
| Kocatürk, Ö | 1 |
| Bianchi, L | 2 |
| Piergiovanni, C | 2 |
| Marietti, R | 2 |
| Renzini, M | 2 |
| Gori, F | 1 |
| Hansel, K | 2 |
| Tramontana, M | 1 |
| Stingeni, L | 2 |
| Yuan, J | 1 |
| Fei, Y | 1 |
| Bavarian, R | 1 |
| Khawaja, SN | 1 |
| Treister, NS | 1 |
| Kiani, CS | 1 |
| Hunt, RW | 1 |
| Hall, EA | 1 |
| Sauer, HE | 1 |
| Davis, MS | 1 |
| Anghelescu, DL | 1 |
| Moisset, X | 1 |
| Bouhassira, D | 4 |
| Attal, N | 5 |
| Sansone, P | 1 |
| Passavanti, MB | 1 |
| Fiorelli, A | 1 |
| Aurilio, C | 1 |
| Colella, U | 1 |
| De Nardis, L | 1 |
| Donatiello, V | 1 |
| Pota, V | 1 |
| Pace, MC | 1 |
| Jeon, Y | 1 |
| Kim, S | 1 |
| Verhagen, T | 1 |
| Loos, MJA | 1 |
| Scheltinga, MRM | 1 |
| Roumen, RMH | 1 |
| Paisley, P | 1 |
| Serpell, M | 2 |
| Katz, P | 1 |
| Pegoraro, V | 1 |
| Liedgens, H | 1 |
| Baraldi, C | 1 |
| Pellesi, L | 1 |
| Guerzoni, S | 1 |
| Cainazzo, MM | 1 |
| Pini, LA | 1 |
| Cheng, YF | 1 |
| Chang, YT | 1 |
| Chen, WH | 1 |
| Shih, HC | 1 |
| Chen, YH | 1 |
| Shyu, BC | 1 |
| Chen, CC | 1 |
| Amato, F | 1 |
| Duse, G | 1 |
| Consoletti, L | 1 |
| Lo Presti, C | 1 |
| Firetto, V | 1 |
| Ciliberto, G | 1 |
| Parigi, LA | 1 |
| Palmieri, V | 1 |
| Mazza, M | 1 |
| Martin, E | 1 |
| Tiberghien, F | 1 |
| Delorme, C | 1 |
| Mick, G | 3 |
| Skyt, I | 2 |
| Moslemi, K | 2 |
| Baastrup, C | 2 |
| Grosen, K | 3 |
| Benedetti, F | 2 |
| Petersen, GL | 2 |
| Price, DD | 2 |
| Hall, KT | 1 |
| Kaptchuk, TJ | 1 |
| Svensson, P | 2 |
| Jensen, TS | 7 |
| Vase, L | 3 |
| Chtompel, Y | 1 |
| Eghtesadi, M | 1 |
| Vargas-Schaffer, G | 1 |
| Principato, M | 1 |
| Rousseau, V | 1 |
| Morelle, M | 1 |
| Arriuberge, C | 1 |
| Darnis, S | 1 |
| Chabaud, S | 1 |
| Launay, V | 1 |
| Thouvenin, S | 1 |
| Roumenoff-Turcant, F | 1 |
| Metzger, S | 1 |
| Tourniaire, B | 1 |
| Marec-Berard, P | 1 |
| Sagalajev, B | 1 |
| Wei, H | 1 |
| Chen, Z | 1 |
| Albayrak, I | 1 |
| Koivisto, A | 1 |
| Pertovaara, A | 1 |
| Kim, YC | 1 |
| Castañeda, AM | 1 |
| Lee, CS | 1 |
| Jin, HS | 1 |
| Park, KS | 1 |
| Moon, JY | 1 |
| Vollert, J | 2 |
| Magerl, W | 1 |
| Baron, R | 6 |
| Binder, A | 3 |
| Enax-Krumova, EK | 1 |
| Geisslinger, G | 1 |
| Gierthmühlen, J | 1 |
| Henrich, F | 1 |
| Hüllemann, P | 1 |
| Klein, T | 1 |
| Lötsch, J | 1 |
| Oertel, B | 1 |
| Schuh-Hofer, S | 1 |
| Tölle, TR | 1 |
| Treede, RD | 1 |
| Marabese, I | 1 |
| Boccella, S | 1 |
| Iannotta, M | 1 |
| Luongo, L | 1 |
| de Novellis, V | 1 |
| Guida, F | 1 |
| Serra, N | 1 |
| Farina, A | 1 |
| Maione, S | 1 |
| Palazzo, E | 1 |
| Ford, AL | 1 |
| Nikolajsen, L | 2 |
| Finnerup, NB | 6 |
| Neiner, A | 1 |
| Kharasch, ED | 1 |
| Karlsson, P | 1 |
| Bottros, MM | 1 |
| Martini, A | 1 |
| Del Balzo, G | 1 |
| Schweiger, V | 3 |
| Zanzotti, M | 1 |
| Picelli, A | 1 |
| Parolini, M | 1 |
| Chinellato, E | 1 |
| Tamburin, S | 2 |
| Polati, E | 3 |
| Thompson, EN | 1 |
| Usichenko, T | 1 |
| Malessy, MJA | 1 |
| de Boer, R | 1 |
| Muñoz Romero, I | 1 |
| Eekhof, JLA | 1 |
| van Zwet, EW | 1 |
| Kliot, M | 1 |
| Dahan, A | 2 |
| Pondaag, W | 1 |
| Palladini, M | 1 |
| Boesl, I | 1 |
| Koenig, S | 1 |
| Buchheister, B | 1 |
| Eker, HE | 2 |
| Yalçın Çok, O | 1 |
| Bozdoğan Özyılkan, N | 1 |
| Arıboğan, A | 2 |
| Khan, JS | 1 |
| Hodgson, N | 1 |
| Choi, S | 1 |
| Reid, S | 1 |
| Paul, JE | 1 |
| Hong, NJL | 1 |
| Holloway, C | 1 |
| Busse, JW | 1 |
| Gilron, I | 1 |
| Buckley, DN | 1 |
| McGillion, M | 1 |
| Clarke, H | 1 |
| Katz, J | 1 |
| Mackey, S | 1 |
| Avram, R | 1 |
| Pohl, K | 1 |
| Rao-Melacini, P | 1 |
| Devereaux, PJ | 1 |
| Tamaki, A | 1 |
| Thuener, J | 1 |
| Weidenbecher, M | 1 |
| Voute, M | 1 |
| Macian, N | 1 |
| Ganry, H | 1 |
| Pereira, B | 1 |
| Yatziv, SL | 1 |
| Devor, M | 4 |
| Zheng, Y | 1 |
| Hou, X | 1 |
| Yang, S | 1 |
| Lancaster, RJ | 1 |
| Wren, K | 1 |
| Hudson, A | 1 |
| Leavitt, K | 1 |
| Albala, M | 1 |
| Tischaefer, D | 1 |
| Wang, R | 1 |
| King, T | 2 |
| De Felice, M | 1 |
| Guo, W | 1 |
| Ossipov, MH | 1 |
| Porreca, F | 2 |
| Martini, CH | 1 |
| Yassen, A | 1 |
| Krebs-Brown, A | 1 |
| Passier, P | 1 |
| Stoker, M | 1 |
| Olofsen, E | 1 |
| Haribabu, PK | 1 |
| Eliav, E | 1 |
| Heir, GM | 2 |
| Paliwal, VK | 1 |
| Pradhan, S | 1 |
| Sokov, EL | 1 |
| Kornilova, LE | 1 |
| Artiukov, OP | 1 |
| Nasri-Heir, C | 1 |
| Khan, J | 1 |
| Quiding, H | 2 |
| Åkermark, C | 1 |
| Segerdahl, M | 1 |
| Reinholdsson, I | 1 |
| Svensson, H | 1 |
| Jonzon, B | 1 |
| Xu, G | 1 |
| Lv, ZW | 1 |
| Xu, GX | 1 |
| Tang, WZ | 1 |
| Garzón-Rodríguez, C | 1 |
| Casals Merchan, M | 1 |
| Calsina-Berna, A | 1 |
| López-Rómboli, E | 1 |
| Porta-Sales, J | 1 |
| Duarte, RV | 1 |
| Raphael, JH | 1 |
| Dimitroulas, T | 1 |
| Sparkes, E | 1 |
| Southall, JL | 1 |
| Ashford, RL | 1 |
| Kitas, GD | 1 |
| Kern, KU | 3 |
| Nowack, W | 1 |
| Poole, C | 1 |
| Fogliardi, A | 2 |
| Brunori, C | 1 |
| Stanos, SP | 1 |
| Galluzzi, KE | 1 |
| Høye, K | 1 |
| Fricová, J | 1 |
| Vanelderen, P | 1 |
| Ernault, E | 1 |
| Siciliano, T | 1 |
| Marques, S | 1 |
| Bendtsen, TF | 1 |
| Kristensen, AD | 1 |
| Hasselstrøm, JB | 1 |
| Vaso, A | 1 |
| Adahan, HM | 1 |
| Gjika, A | 1 |
| Zahaj, S | 1 |
| Zhurda, T | 1 |
| Vyshka, G | 1 |
| Khot, S | 1 |
| Morgan, CL | 1 |
| Kadambande, S | 1 |
| Poole, CD | 1 |
| Casale, R | 1 |
| Coluzzi, F | 1 |
| Bhaskar, A | 1 |
| Consalvo, M | 1 |
| Derry, S | 1 |
| Wiffen, PJ | 1 |
| Moore, RA | 1 |
| Quinlan, J | 1 |
| Magrinelli, F | 1 |
| Brugnoli, MP | 1 |
| Zanette, G | 1 |
| Salas, S | 1 |
| Auquier, P | 1 |
| Duffaud, F | 1 |
| Garnier, SR | 1 |
| Deschamps, M | 1 |
| Honoré, S | 1 |
| Sudour, P | 1 |
| Baumstarck, K | 1 |
| Pilegaard, HK | 1 |
| Tracey, I | 1 |
| Woo, JH | 2 |
| Park, HS | 2 |
| Provinciali, L | 1 |
| Lattanzi, S | 1 |
| Chiarlone, R | 1 |
| Intelligente, F | 1 |
| Irace, C | 1 |
| Lanzilotta, M | 1 |
| Palomba, R | 1 |
| Storelli, E | 1 |
| Zampi, M | 1 |
| Rossaneis, AC | 1 |
| Genaro, K | 1 |
| Dias, QM | 1 |
| Guethe, LM | 1 |
| Fais, RS | 1 |
| Del Bel, EA | 1 |
| Prado, WA | 1 |
| Hutson, P | 1 |
| Backonja, M | 1 |
| Knurr, H | 1 |
| Kastler, A | 1 |
| Onana, Y | 1 |
| Comte, A | 1 |
| Attyé, A | 1 |
| Lajoie, JL | 1 |
| Kastler, B | 1 |
| Demant, DT | 1 |
| Lund, K | 1 |
| Segerdahl, MS | 1 |
| Sindrup, SH | 1 |
| Song, T | 1 |
| Wang, W | 1 |
| Wang, H | 1 |
| Yang, Y | 1 |
| Yang, L | 1 |
| Ma, P | 1 |
| Ma, X | 1 |
| Zhao, J | 1 |
| Yan, R | 1 |
| Guan, J | 1 |
| Wang, C | 1 |
| Qi, Y | 1 |
| Ya, J | 1 |
| Cheng, KI | 2 |
| Wang, HC | 2 |
| Wu, YC | 1 |
| Tseng, KY | 1 |
| Chuang, YT | 1 |
| Chou, CW | 1 |
| Chen, PL | 1 |
| Chang, LL | 2 |
| Lai, CS | 2 |
| Manchikanti, L | 1 |
| Boswell, MV | 1 |
| Kaye, AD | 1 |
| Hirsch, JA | 1 |
| Cohen, SP | 1 |
| Peterlin, BL | 1 |
| Fulton, L | 1 |
| Neely, ET | 1 |
| Kurihara, C | 1 |
| Gupta, A | 1 |
| Mali, J | 1 |
| Fu, DC | 1 |
| Jacobs, MB | 1 |
| Plunkett, AR | 1 |
| Verdun, AJ | 1 |
| Stojanovic, MP | 1 |
| Hanling, S | 1 |
| Constantinescu, O | 1 |
| White, RL | 1 |
| McLean, BC | 1 |
| Pasquina, PF | 1 |
| Zhao, Z | 1 |
| Xu, ZZ | 1 |
| Kim, YH | 1 |
| Bang, S | 1 |
| Berta, T | 1 |
| Wang, F | 1 |
| Oh, SB | 1 |
| Ji, RR | 1 |
| Peirs, C | 1 |
| Seal, RP | 1 |
| Weiser, T | 1 |
| Kingwell, K | 1 |
| Allegri, M | 1 |
| Hans, G | 2 |
| Correa-Illanes, G | 2 |
| Mayoral Rojals, V | 1 |
| van der Wal, SE | 1 |
| van den Heuvel, SA | 1 |
| Radema, SA | 1 |
| van Berkum, BF | 1 |
| Vaneker, M | 1 |
| Steegers, MA | 1 |
| Scheffer, GJ | 1 |
| Vissers, KC | 1 |
| Havelin, J | 1 |
| Imbert, I | 1 |
| Cormier, J | 1 |
| Allen, J | 1 |
| Freo, U | 2 |
| Ambrosio, F | 2 |
| Furnari, M | 1 |
| Ori, C | 2 |
| Przeklasa-Muszyńska, A | 1 |
| Kocot-Kępska, M | 1 |
| Dobrogowski, J | 1 |
| Wiatr, M | 1 |
| Mika, J | 1 |
| Colloca, L | 1 |
| Ludman, T | 1 |
| Dickenson, AH | 1 |
| Yarnitsky, D | 1 |
| Freeman, R | 1 |
| Truini, A | 1 |
| Eccleston, C | 1 |
| Kalso, E | 1 |
| Bennett, DL | 1 |
| Dworkin, RH | 7 |
| Raja, SN | 1 |
| Ling, B | 1 |
| Coudoré, F | 1 |
| Decalonne, L | 1 |
| Eschalier, A | 1 |
| Authier, N | 1 |
| Yamamoto, T | 1 |
| Cheville, AL | 1 |
| Sloan, JA | 1 |
| Northfelt, DW | 1 |
| Jillella, AP | 1 |
| Wong, GY | 1 |
| Bearden Iii, JD | 1 |
| Liu, H | 1 |
| Schaefer, PL | 1 |
| Marchello, BT | 1 |
| Christensen, BJ | 1 |
| Loprinzi, CL | 1 |
| Thomas, J | 1 |
| Gormsen, L | 1 |
| Almqvist, PM | 1 |
| Murata, Y | 1 |
| Kato, Y | 1 |
| Miyamoto, K | 1 |
| Takahashi, K | 1 |
| Joukes, E | 1 |
| Verhulst, J | 1 |
| Vercauteren, M | 1 |
| O'Connor, AB | 1 |
| Wilhelm, IR | 1 |
| Tzabazis, A | 1 |
| Likar, R | 1 |
| Sittl, R | 1 |
| Griessinger, N | 1 |
| Otsuru, N | 1 |
| Inui, K | 1 |
| Yamashiro, K | 1 |
| Miyazaki, T | 2 |
| Takeshima, Y | 1 |
| Kakigi, R | 1 |
| Isose, S | 1 |
| Misawa, S | 1 |
| Sakurai, K | 1 |
| Kanai, K | 1 |
| Shibuya, K | 1 |
| Sekiguchi, Y | 1 |
| Nasu, S | 1 |
| Noto, Y | 1 |
| Fujimaki, Y | 1 |
| Yokote, K | 1 |
| Kuwabara, S | 1 |
| Carroll, IR | 2 |
| Younger, JW | 1 |
| Mackey, SC | 2 |
| Buchanan, DD | 1 |
| J MacIvor, F | 1 |
| Romanzi, L | 1 |
| Kohl, M | 1 |
| Kiefer, RT | 1 |
| Mahn, F | 1 |
| Plested, M | 1 |
| Budhia, S | 1 |
| Gabriel, Z | 1 |
| Joo, JD | 1 |
| Choi, JW | 1 |
| In, JH | 1 |
| Jung, HS | 1 |
| Lee, JA | 1 |
| Kim, YS | 1 |
| Kim, DW | 1 |
| Yeom, JH | 1 |
| Shin, EY | 1 |
| Jeon, YS | 1 |
| Wang, FY | 1 |
| Ho, ST | 1 |
| Tsai, HP | 1 |
| Kwan, AL | 1 |
| Viana, M | 1 |
| Glastonbury, CM | 1 |
| Sprenger, T | 1 |
| Goadsby, PJ | 1 |
| Gustorff, B | 1 |
| Hauer, D | 1 |
| Thaler, J | 1 |
| Seis, A | 1 |
| Draxler, J | 1 |
| Uzaraga, I | 1 |
| Gerbis, B | 1 |
| Holwerda, E | 1 |
| Gillis, D | 1 |
| Wai, E | 1 |
| Mert, T | 2 |
| Gunes, Y | 2 |
| Gunay, I | 2 |
| Jääskeläinen, SK | 1 |
| Douchamps, F | 1 |
| Courtois, AC | 1 |
| Bruyère, PJ | 1 |
| Crielaard, JM | 1 |
| Parnell, BA | 1 |
| Johnson, EA | 1 |
| Zolnoun, DA | 1 |
| Cok, OY | 1 |
| Arslan, G | 1 |
| Kesselheim, AS | 1 |
| Myers, JA | 1 |
| Solomon, DH | 1 |
| Winkelmayer, WC | 1 |
| Levin, R | 1 |
| Avorn, J | 1 |
| Jürgens, TP | 1 |
| Müller, P | 1 |
| Seedorf, H | 1 |
| Regelsberger, J | 1 |
| May, A | 1 |
| Berger, A | 1 |
| Sadosky, A | 1 |
| Dukes, E | 1 |
| Edelsberg, J | 1 |
| Oster, G | 1 |
| Kajiume, T | 1 |
| Sera, Y | 1 |
| Nakanuno, R | 1 |
| Ogura, T | 1 |
| Karakawa, S | 1 |
| Kobayakawa, M | 1 |
| Taguchi, S | 1 |
| Oshita, K | 1 |
| Kawaguchi, H | 1 |
| Sato, T | 1 |
| Kobayashi, M | 1 |
| Stuginski-Barbosa, J | 1 |
| Murayama, RA | 1 |
| Conti, PC | 1 |
| Speciali, JG | 1 |
| Kopsky, DJ | 1 |
| Amelink, GJ | 1 |
| Keppel Hesselink, JM | 1 |
| Müller-Schwefe, GH | 1 |
| Shen, J | 1 |
| Fox, LE | 1 |
| Cheng, J | 1 |
| Zakir, HM | 1 |
| Mostafeezur, RM | 1 |
| Suzuki, A | 1 |
| Hitomi, S | 1 |
| Suzuki, I | 1 |
| Maeda, T | 1 |
| Seo, K | 1 |
| Yamada, Y | 1 |
| Yamamura, K | 1 |
| Lev, S | 1 |
| Binshtok, AM | 1 |
| Iwata, K | 1 |
| Kitagawa, J | 1 |
| López Ramírez, E | 1 |
| Orellana Silva, M | 1 |
| Yañez, V | 1 |
| Hidalgo, G | 1 |
| Valenzuela, F | 1 |
| Saavedra, R | 1 |
| Galer, BS | 10 |
| Gintautas, J | 1 |
| Abraham, Y | 1 |
| Doss, NW | 1 |
| Ghobriel, A | 1 |
| Kashem, A | 1 |
| Fogler, RJ | 1 |
| Ahmad, M | 1 |
| Goucke, CR | 1 |
| Erichsen, HK | 1 |
| Hao, JX | 1 |
| Xu, XJ | 1 |
| Blackburn-Munro, G | 1 |
| Gammaitoni, AR | 4 |
| Schmader, KE | 1 |
| Araujo, MC | 1 |
| Sinnott, CJ | 2 |
| Strichartz, GR | 3 |
| Isaac, R | 1 |
| Kvarnström, A | 1 |
| Karlsten, R | 1 |
| Emanuelsson, BM | 1 |
| Gordh, T | 1 |
| LESKIEN, O | 2 |
| MCNEILL, RA | 1 |
| Pasero, C | 1 |
| Rouaud, J | 1 |
| Brasseur, L | 2 |
| Chauvin, M | 2 |
| White, WT | 1 |
| Patel, N | 1 |
| Drass, M | 1 |
| Sukhotinsky, I | 1 |
| Ben-Dor, E | 1 |
| Raber, P | 1 |
| Nicholson, BD | 1 |
| Zhang, JM | 1 |
| Li, H | 1 |
| Munir, MA | 1 |
| Davies, PS | 4 |
| Simpson, MA | 1 |
| Rodrigues-Filho, R | 1 |
| Campos, MM | 1 |
| Ferreira, J | 1 |
| Santos, AR | 1 |
| Bertelli, JA | 1 |
| Calixto, JB | 1 |
| Neafsey, PJ | 1 |
| Dubinsky, RM | 1 |
| Kabbani, H | 1 |
| El-Chami, Z | 1 |
| Boutwell, C | 1 |
| Ali, H | 1 |
| Wepner, U | 1 |
| Jensen, MP | 4 |
| Oleka, N | 2 |
| Hayashida, M | 1 |
| Fukuda, K | 1 |
| Fukunaga, A | 1 |
| Meno, A | 1 |
| Sato, K | 1 |
| Tarui, K | 1 |
| Arita, H | 1 |
| Kaneko, Y | 1 |
| Hanaoka, K | 2 |
| Olaleye, DO | 2 |
| Wasner, G | 1 |
| Kleinert, A | 1 |
| Schattschneider, J | 1 |
| Hempenstall, K | 1 |
| Nurmikko, TJ | 1 |
| Johnson, RW | 1 |
| A'Hern, RP | 1 |
| Rice, AS | 1 |
| Tei, Y | 1 |
| Morita, T | 1 |
| Shishido, H | 1 |
| Inoue, S | 1 |
| Alvarez, NA | 1 |
| Yi, X | 1 |
| Cook, AJ | 1 |
| Hamill-Ruth, RJ | 1 |
| Rowlingson, JC | 1 |
| Herrmann, DN | 1 |
| Pannoni, V | 1 |
| Barbano, RL | 1 |
| Pennella-Vaughan, J | 1 |
| Rozen, TD | 1 |
| Burgess, C | 1 |
| Ravenscroft, AJ | 1 |
| Naja, MZ | 1 |
| Al-Tannir, MA | 1 |
| Maaliki, H | 1 |
| El-Rajab, M | 1 |
| Ziade, MF | 1 |
| Zeidan, A | 1 |
| Ozcengiz, D | 1 |
| Polat, S | 1 |
| Ebell, MH | 1 |
| Malmstrom, K | 1 |
| Kotey, P | 1 |
| McGratty, M | 1 |
| Ramakrishnan, R | 1 |
| Gottesdiener, K | 1 |
| Reicin, A | 1 |
| Wagner, JA | 1 |
| Bruera, E | 1 |
| Ripamonti, C | 1 |
| Brenneis, C | 1 |
| Macmillan, K | 1 |
| Hanson, J | 1 |
| Lee, SE | 1 |
| Kim, JH | 1 |
| ter Meulen, BC | 1 |
| Peters, EW | 1 |
| Wijsmuller, A | 1 |
| Kropman, RF | 1 |
| Mosch, A | 1 |
| Tavy, DL | 1 |
| Takahashi Sato, K | 1 |
| Suzuki, M | 1 |
| Izuha, A | 1 |
| Hayashi, S | 1 |
| Isosu, T | 1 |
| Murakawa, M | 1 |
| Robert, DN | 1 |
| Van Maldeghem, KN | 1 |
| Aydin, O | 1 |
| Ozturk, M | 1 |
| Anik, Y | 1 |
| Kaplan, KM | 1 |
| Nayak, S | 1 |
| Cunliffe, M | 1 |
| Thiers, BH | 1 |
| Schreuder, M | 2 |
| Ogata, A | 1 |
| Tomoda, T | 1 |
| Tanaka, S | 1 |
| Kudo, S | 1 |
| Rifat, SF | 1 |
| Lombardo, JA | 1 |
| Nagaro, T | 1 |
| Shimizu, C | 1 |
| Inoue, H | 1 |
| Fujitani, T | 1 |
| Adachi, N | 1 |
| Amakawa, K | 1 |
| Kimura, S | 1 |
| Arai, T | 1 |
| Watanabe, T | 1 |
| Oka, S | 1 |
| Rowbotham, MC | 7 |
| Fields, HL | 3 |
| Thakur, BK | 1 |
| Murali, MR | 1 |
| Riopelle, J | 1 |
| Lopez-Anaya, A | 1 |
| Cork, RC | 1 |
| Heitler, D | 1 |
| Eyrich, J | 1 |
| Dunston, A | 1 |
| Riopelle, AJ | 1 |
| Johnson, W | 1 |
| Ragan, A | 1 |
| Naraghi, M | 1 |
| Avidan, A | 1 |
| Litman, SJ | 1 |
| Vitkun, SA | 1 |
| Poppers, PJ | 1 |
| Harle, J | 1 |
| Verkempinck, C | 1 |
| Kurvers, HA | 1 |
| Tangelder, GJ | 1 |
| De Mey, JG | 1 |
| Slaaf, DW | 1 |
| Beuk, RJ | 1 |
| van den Wildenberg, FA | 1 |
| Kitslaar, PJ | 1 |
| Reneman, RS | 1 |
| Jacobs, MJ | 1 |
| Chiarello, SE | 1 |
| Kayser, V | 1 |
| Idänpään-Heikkilä, JJ | 1 |
| Guilbaud, G | 1 |
| Verdugo, RJ | 1 |
| Ochoa, JL | 1 |
| Tamakawa, S | 1 |
| Ogawa, H | 1 |
| Abdi, S | 1 |
| Lee, DH | 1 |
| Chung, JM | 1 |
| Ozawa, A | 1 |
| Haruki, Y | 1 |
| Iwashita, K | 1 |
| Sasao, Y | 1 |
| Miyahara, M | 1 |
| Sugai, J | 1 |
| Matsuyama, T | 1 |
| Iizuka, M | 1 |
| Kawakubo, Y | 1 |
| Nakamori, M | 1 |
| Ohkido, M | 1 |
| Perander, J | 1 |
| Friedman, E | 1 |
| Garfield, JM | 1 |
| Fuchs, PN | 1 |
| Pappagallo, M | 1 |
| Meyer, RA | 1 |
| Baranowski, AP | 1 |
| De Courcey, J | 1 |
| Bonello, E | 1 |
| Tajti, J | 1 |
| Szok, D | 1 |
| Vécsei, L | 1 |
| Comer, AM | 1 |
| Lamb, HM | 1 |
| Mao, J | 1 |
| Chen, LL | 1 |
| Ben-David, B | 1 |
| Maryanovsky, M | 1 |
| Gurevitch, A | 1 |
| Lucyk, C | 1 |
| Solosko, D | 1 |
| Frankel, R | 1 |
| Volpin, G | 1 |
| DeMeo, PJ | 1 |
| Kotani, N | 1 |
| Kushikata, T | 1 |
| Hashimoto, H | 1 |
| Kimura, F | 1 |
| Muraoka, M | 1 |
| Yodono, M | 1 |
| Asai, M | 1 |
| Matsuki, A | 1 |
| Watson, CP | 1 |
| Iseki, M | 1 |
| Mitsuhata, H | 1 |
| Toriumi, E | 1 |
| Yoshino, K | 1 |
| Zetlaoui, PJ | 1 |
| Cosserat, J | 1 |
| Lewis, G | 1 |
| Niebergall, H | 1 |
| Priebe, HJ | 1 |
| Srinivasan, B | 1 |
| Mizuno, J | 1 |
| Sugimoto, S | 1 |
| Ikeda, M | 2 |
| Machida, K | 1 |
| Mikawa, Y | 1 |
| Sekiyama, H | 1 |
| Bileviciute-Ljungar, I | 1 |
| Biella, G | 1 |
| Bellomi, P | 1 |
| Sotgiu, ML | 2 |
| Zhou, Z | 1 |
| Sinnott, C | 1 |
| Khodorova, A | 1 |
| Campbell, BJ | 1 |
| Rowbotham, M | 1 |
| Jacob, P | 1 |
| Benowitz, NL | 1 |
| Thompson, JE | 2 |
| Cox, CL | 1 |
| Cocks, GR | 1 |
| Fothergill, WT | 2 |
| DeSaussure, RL | 1 |
| Goecke, C | 1 |
| Marchettini, P | 1 |
| Lacerenza, M | 1 |
| Marangoni, C | 1 |
| Pellegata, G | 1 |
| Smirne, S | 1 |
| Arnér, S | 1 |
| Lindblom, U | 1 |
| Meyerson, BA | 1 |
| Molander, C | 1 |
| Reisner-Keller, LA | 1 |
| Currey, TA | 1 |
| Dalsania, J | 1 |
| Tanelian, DL | 1 |
| Brose, WG | 1 |
| Rogers, N | 1 |
| Wheeler, JG | 1 |
| Stow, PJ | 1 |
| Glynn, CJ | 1 |
| Minor, B | 1 |
| Kissin, I | 1 |
| McDanal, J | 1 |
| Xavier, AV | 1 |
| Sandrock, NJ | 1 |
| Warfield, CA | 1 |
| Stadtner, DA | 1 |
| Zinke, R | 1 |
| Ninaber, V | 1 |
| Thick, GC | 1 |
| Omer, GE | 1 |
| Thomas, SR | 1 |
| Patman, RD | 1 |
| Persson, AV | 1 |
| Gale, DA | 1 |
| Colding, A | 1 |
| Marton, S | 1 |
| Guntheroth, WG | 1 |
| Chakmakjian, S | 1 |
| Brena, SC | 1 |
| Ricketts, HJ | 1 |
| Wiederhielm, CA | 1 |
| André, W | 1 |
| Laporte, MG | 1 |
| Muratore, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Physical and Psychological Changes in Complex Regional Pain Syndrome (CRPS) Patients Undergoing Multimodal Rehabilitation[NCT05696587] | 42 participants (Actual) | Interventional | 2021-10-10 | Completed | |||
| Investigation of the Presence of Piriformis Syndrome Accompanying Lumbar Radiculopathy[NCT05392933] | 40 participants (Anticipated) | Interventional | 2023-01-15 | Not yet recruiting | |||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| Observational, Prospective, Monocentric Study, Assessing the Use of Rechargeable Spinal Cord Stimulators for the Treatment of Neuropathic Pain. Quantitative and Qualitative Evaluation Protocol[NCT05373654] | 160 participants (Anticipated) | Interventional | 2023-01-31 | Recruiting | |||
| Randomized Trial Evaluating Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis - RELIEF-SCC[NCT04614610] | Phase 2 | 100 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain: Randomized, Controlled, Comparative Study[NCT02597257] | Phase 2 | 44 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Paravertebral Block Versus Simultaneous Ketamine and Lidocaine Infusions for Pain Management in Rib Fracture Patients[NCT04413799] | Early Phase 1 | 170 participants (Anticipated) | Interventional | 2020-09-01 | Recruiting | ||
| The Significance of Peripheral Input in Patients With Post Surgery Neuropathic Pain: Evaluation of Trigger Point Anesthesia. A Double-blind, Randomized, Controlled Exploratory Study[NCT04764045] | 12 participants (Anticipated) | Interventional | 2019-11-20 | Recruiting | |||
| Efficacy and Safety of Lidocaine 5% Medicated Plaster in Localized Chronic Post-operative Neuropathic Pain[NCT01752322] | Phase 3 | 444 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Pregabalin and Lidocaine in Breast Cancer Surgery to Alter Neuropathic Pain (PLAN): A Pilot Trial[NCT02240199] | Phase 3 | 100 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Impact of 5% Lidocaine Medicated Plaster on Allodynic Symptoms of Localized Neuropathic Pain After Knee Surgery[NCT02763592] | Phase 2 | 37 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Preventive Application Of Lidocaine Patch In Adjunction To Intravenous Morphine Analgesia For Management Of Post-Thoracotomy Pain: Results Of A Randomized, Double Blind, Placebo Controlled Study[NCT02751619] | 90 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| Trial Evaluating multimOdal toPical Cream In CompArison to pLacebo (TOPICAL)[NCT03199417] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2017-05-01 | Terminated (stopped due to Terminated prematurely due to feasibility issues with rate of recruitment) | ||
| The PATCH Trial: Effectiveness and Safety of 5% Lidocaine-medicated Plaster for the Treatment of Trigeminal Neuralgia[NCT04570293] | Phase 4 | 226 participants (Actual) | Interventional | 2021-05-01 | Completed | ||
| Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.[NCT02137954] | Phase 3 | 200 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| Comparison of Heated vs. Pulsed Radiofrequency Treatment of the Genicular Nerves for Osteoarthritis Knee Pain[NCT04379895] | 60 participants (Anticipated) | Interventional | 2020-06-30 | Not yet recruiting | |||
| A Comparison of Pain Control AND Quality of Life Improvement Between Occipital Nerve Block And Occipital Nerve Radiofrequency Ablation: A Double-Blind Single Center Prospective Study[NCT04124458] | 70 participants (Anticipated) | Interventional | 2023-01-02 | Not yet recruiting | |||
| Pulsed vs Continuous Radiofrequency Neurotomy for Cervical Facet Joint Mediated Pain: a Single-blind Randomized Controlled Clinical Trial[NCT04124445] | 88 participants (Anticipated) | Interventional | 2020-02-10 | Recruiting | |||
| Randomized, Double-blind, Comparative-effectiveness Study Comparing Corticosteroid Injections to Pulsed Radiofrequency for Occipital Neuralgia[NCT01670825] | 81 participants (Actual) | Interventional | 2012-08-31 | Completed | |||
| Greater Occipital Nerve Pulsed Radiofrequency for the Treatment of Combined Migraine and Cervicogenic Headache (New Approach): Randomized Clinical Trial[NCT06121037] | 60 participants (Actual) | Interventional | 2022-01-01 | Completed | |||
| POPARTS Study- Post-Operative Pain After Recovery in Thoracic Surgery: Evaluation of the Persistence of Painful Symptoms and the Incidence of Neuropathic Pain After Resective Lung Surgery[NCT04300660] | 250 participants (Anticipated) | Observational [Patient Registry] | 2017-10-25 | Recruiting | |||
| Do Cervical Interlaminar Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness? A Prospective Randomized[NCT03382925] | Phase 4 | 16 participants (Actual) | Interventional | 2017-12-20 | Terminated (stopped due to Not enough cervical interlaminar patients who meet criteria in order to meet recruitment goals.) | ||
| BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome: a Multicenter, Randomized, Doubleblind, Placebo-controlled Study[NCT05411900] | Phase 2 | 164 participants (Anticipated) | Interventional | 2022-05-25 | Recruiting | ||
| Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety[NCT05427058] | 36 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
| Neuropathic Foot and Ankle in Rheumatoid Arthritis : Ultrasound and Nerve Conduction Study[NCT04550884] | 80 participants (Anticipated) | Observational | 2020-10-31 | Not yet recruiting | |||
| NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial[NCT04808531] | Phase 3 | 360 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| The Efficacy Of Lidocaine Patch In The Management Of Postsurgical Neuropathic Pain In Patients With Cancer: A Phase III Double-Blind, Crossover Study[NCT00058357] | Phase 3 | 30 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Randomized Controlled Trial of Lidocaine Patch for Lower Limb Amputation Pain[NCT02696720] | Phase 2 | 0 participants (Actual) | Interventional | 2016-05-13 | Withdrawn (stopped due to Lack of recruitment) | ||
| Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain[NCT03210766] | 20 participants (Actual) | Observational | 2014-09-01 | Completed | |||
| The Study of Perioperative Intravenous Infusion of Lidocaine on Postoperative Analgesia in Patients Undergoing Single-port Thoracoscopic[NCT04043624] | Phase 4 | 80 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine[NCT03096444] | Phase 2 | 13 participants (Actual) | Interventional | 2017-05-23 | Terminated (stopped due to Efficacy was not seen after interim analysis) | ||
| Cognitive Changes Associated With Initiation of Gabapentin Treatment in Adults With Chronic Pain[NCT04106011] | 3 participants (Actual) | Observational | 2020-01-10 | Terminated (stopped due to PI request - low enrollment) | |||
| The Safety and Efficacy of 5% Lidocaine Patch and Flurbiprofen Patch for Relieving Acute Low Back Pain[NCT03171987] | Phase 4 | 120 participants (Anticipated) | Interventional | 2017-06-14 | Recruiting | ||
| Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain : A Pilot Study[NCT02217267] | Phase 3 | 29 participants (Actual) | Interventional | 2014-08-01 | Completed | ||
| Intravenous Lidocaine for Preventing Painful Oxaliplatin-induced Peripheral Neuropathy (OIPN)[NCT03254394] | Phase 1/Phase 2 | 26 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| VERSATIS - Efficacy and Safety of Lidocaine 5% Plasters (Versatis® 5%) in Child, Adolescents and Young Adults With Neuropathic Pains or Vasoocclusive Sickle Cell Crisis Pains[NCT01314300] | Phase 2 | 39 participants (Anticipated) | Interventional | 2011-03-31 | Completed | ||
| Intravenous Lidocaine for Perioperative and Postoperative Analgesia[NCT03921567] | Phase 4 | 520 participants (Anticipated) | Interventional | 2019-04-15 | Recruiting | ||
| Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)[NCT01623271] | 5 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to Due to limited population of research participants.) | |||
| Does Repetitive Peripheral Nerve Blocks Vs Single Peripheral Nerve Block Vs Standard Medical Treatment Provide a Better Pain Relief on Zoster Pain at the Acute Phase and Reduce the Risk of Post Herpetic Neuralgia?[NCT04133142] | 0 participants (Actual) | Interventional | 2020-05-15 | Withdrawn (stopped due to No enrollement and covid) | |||
| Local Anaesthetic Effects of Transcutaneous Amitriptyline in Human Volunteers : a Controlled, Double-blinded, Randomised Study Versus Placebo and Transcutaneous Local Anaesthetic (EMLA(R))[NCT00355277] | Phase 1 | 16 participants | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.495 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 3.694 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.791 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.441 |
The change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.312 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.765 |
The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.068 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 3.738 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.392 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.220 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.000 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.694 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.761 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.556 |
This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.678 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.410 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.540 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.650 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.522 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.417 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.761 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.556 |
This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.583 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.825 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 9.539 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 9.069 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 9.256 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 9.431 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 10.025 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 8.132 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 11.333 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 11.972 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 12.590 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 12.250 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 12.775 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 10.842 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.726 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 5.846 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.850 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.149 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.705 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.541 |
The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.354 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.064 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 59.718 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 60.556 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 59.641 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 61.389 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 60.087 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 59.553 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 3 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.087 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.263 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.044 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.368 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.708 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.810 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: 3 months
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.846 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.919 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.128 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.162 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.436 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.436 |
"Peak itch intensity between the vehicle and 4 other active treatments (individual ketamine, amitriptyline, or lidocaine, and KeAmLi-combo). Itch intensity was measured on a 100mm scale visual analog scale for 10 minutes. 0 was weighted with no itch and 100 was weighted with most itch imaginable." (NCT03096444)
Timeframe: 10 minutes
| Intervention | Intensity score (Mean) |
|---|---|
| Topical KeAmLi Combo | 62.7 |
| Topical Ketamine | 63.1 |
| Topical Amitriptyline | 69.2 |
| Topical Lidocaine | 65.8 |
| Topical Vehicle | 61.9 |
Assess mechanical detection and pain thresholds using von Frey filaments stimulators (measured in force mN) to calculate the final threshold as the geometric mean of five series of ascending and descending stimuli. (NCT03096444)
Timeframe: 5 minutes
| Intervention | mN (Mean) | |
|---|---|---|
| Mechanical Detection Threshold | Mechanical Pain Threshold | |
| Topical Amitriptyline | 3.573423965 | 152.4768146 |
| Topical KeAmLi Combo | 3.519376956 | 152.3293608 |
| Topical Ketamine | 3.464204768 | 135.9 |
| Topical Lidocaine | 3.546037659 | 126.9 |
| Topical Vehicle | 3.525692637 | 148.7138273 |
Two standardized quantitative sensory tests are performed to measure warmth detection threshold (assesses the threshold of which warmth sensation is first detected) and heat pain threshold (assesses the threshold at which heat pain sensation is first detected). Measured in change in celsius. (NCT03096444)
Timeframe: 3 minutes
| Intervention | Degrees celsius (Mean) | |
|---|---|---|
| Warm Detection Threshold | Heat Pain Threshold | |
| Topical Amitriptyline | 33.9 | 40.0 |
| Topical KeAmLi Combo | 33.6 | 39.8 |
| Topical Ketamine | 34.0 | 40.0 |
| Topical Lidocaine | 33.7 | 39.4 |
| Topical Vehicle | 33.8 | 39.7 |
The cumulative dose of oxaliplatin received over the course (up to 12 cycles) of mFOLFOX6 treatment regimen. It corresponds to the absolute summed up quantity of Oxaliplatin administered to the patient over time. There is no range for this measure. Since this is a dose-limiting neuropathy prevention study, the higher value can be interpreted as better outcome. (NCT03254394)
Timeframe: 24 weeks
| Intervention | mg (Mean) |
|---|---|
| Placebo + FOLFOX | 1161.8 |
| Lidocaine + FOLFOX | 1294.8 |
"The intensity of cold pain and cold unpleasantness is evaluated separately, assessed daily on a 0-10 scale, upon holding a pre-cooled (~8°C) metal cylinder for 10 seconds. the area under the curve of cold pain and cold unpleasantness vs time is calculated per chemotherapy cycle (every two weeks) and serves as a primary outcome measure.~For intervention (lidocaine+FOLFOX) and control (placebo+FOLFOX) groups, the average of cold pain AUC and cold unpleasantness AUC over 7 cycles was calculated. The average AUCs over 7 cycles were compared between study arms.~The AUC is measured as a score on a 0-10 scale multiplied by 14 days and may range between 0 and 140. Higher AUC values represent more intense cold pain/unpleasantness." (NCT03254394)
Timeframe: 14 weeks
| Intervention | score on a scale*days (Mean) | |
|---|---|---|
| pain AUC | unpleasantness AUC | |
| Lidocaine + FOLFOX | 9.5 | 25.4 |
| Placebo + FOLFOX | 16.4 | 33.1 |
Changes in Neuropathic Pain Symptom Inventory (NPSI) descriptors of neuropathic pain over time from baseline to cycle 3(6 weeks), cycle 6 (12 weeks), and the last follow-up (34-36 weeks). The total NPSI score ranges from 0 to 100; a higher NPSI total score represents a worse neuropathy outcome. The changes in scores from baseline are compared between study arms. (NCT03254394)
Timeframe: 6 weeks, 12 weeks, 34-36 weeks
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| 6 weeks visit | 12 weeks visit | last follow-up visit | |
| Lidocaine + FOLFOX | 0 | 0 | 13.5 |
| Placebo + FOLFOX | 0 | 0 | 3.0 |
"Change in CIPN (Chemotherapy-induced peripheral Neuropathy) score (on EORTC QLQ-CIPN20 tool ) from baseline to the Cycle 6 (12 weeks), and from baseline to last follow-up (34-36 weeks). EORTC QLQ-CIPN20 ranges from 0 (no symptoms) to 100 (worst symptoms). A higher score represents worse neuropathy. The changes in scores are compared between study arms.~EORTC QLQ-CIPN20 tool is a quality of life questionnaire (QLQ) from the European Organization for Research and Treatment of Cancer (EORTC) for evaluation of CIPN." (NCT03254394)
Timeframe: 12 weeks and 34-36 weeks
| Intervention | score on a scale (Median) | |
|---|---|---|
| 12 | 34-36 weeks | |
| Lidocaine + FOLFOX | 4 | 37.0 |
| Placebo + FOLFOX | 2 | 17.0 |
Subjects rated their pain using the VAS at visit 3, which was the last day of their maintenance phase. After this visit, subjects begin to taper the gralise. The VAS is subject reported on a scale of 0-10 with 0 being no pain and 10 being the worst pain they can imagine. Results reported are an average of the 3 subjects who completed visit 3. (NCT01623271)
Timeframe: At visit 3
| Intervention | units on the VAS (Mean) |
|---|---|
| CRPS I Pain Subjects | 3.67 |
40 reviews available for lidocaine and Nerve Pain
| Article | Year |
|---|---|
Trigeminal Traumatic Neuroma: a Comprehensive Review of the Literature Based On a Rare Case.
Topics: Administration, Topical; Humans; Lidocaine; Neuralgia; Neuroma; Pain Management | 2022 |
Intravenous Lidocaine in Chronic Neuropathic Pain: A Systematic Review.
Topics: Adult; Chronic Pain; Diabetic Neuropathies; Humans; Lidocaine; Neuralgia; Peripheral Nerve Injuries; | 2022 |
Effect and safety profile of topical lidocaine on post-surgical neuropathic pain and quality of life: A systematic review and meta-analysis.
Topics: Humans; Lidocaine; Neuralgia; Pain Management; Pain, Postoperative; Quality of Life | 2024 |
Utility of lidocaine as a topical analgesic and improvements in patch delivery systems.
Topics: Administration, Cutaneous; Analgesics; Humans; Lidocaine; Neuralgia; Transdermal Patch | 2020 |
Topical Treatment of Localized Neuropathic Pain in the Elderly.
Topics: Administration, Topical; Aged; Aged, 80 and over; Analgesics; Capsaicin; Humans; Lidocaine; Middle A | 2020 |
Multiple lidocaine infusions for relief of neuropathic pain: systematic review and meta-analysis.
Topics: Anesthetics, Local; Humans; Infusions, Intravenous; Lidocaine; Neuralgia | 2020 |
Is systemic administration of local anesthetic agents effective for relieving neuropathic pain? A Cochrane Review summary with commentary.
Topics: Anesthetics, Local; Humans; Lidocaine; Mexiletine; Neuralgia; Randomized Controlled Trials as Topic; | 2020 |
Multiple lidocaine infusions for relief of neuropathic pain: systematic review and meta-analysis.
Topics: Anesthetics, Local; Humans; Infusions, Intravenous; Lidocaine; Neuralgia; Treatment Outcome | 2020 |
Lidocaine Infusions for Pain Management in Pediatrics.
Topics: Adolescent; Anesthesia, Local; Anesthetics, Local; Child; Chronic Pain; Female; Humans; Infusions, I | 2021 |
French guidelines for neuropathic pain: An update and commentary.
Topics: Analgesics, Opioid; Antidepressive Agents; Humans; Lidocaine; Neuralgia; Selective Serotonin Reuptak | 2021 |
The role of topiceuticals in cancer pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Anesthetics, Local; Cancer Pain; Capsaicin; Clinical | 2017 |
Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.
Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Fructose; Gabapentin; gamm | 2017 |
Localized neuropathic pain: an expert consensus on local treatments.
Topics: Administration, Topical; Aged; Analgesics; Anesthetics, Local; Animals; Capsaicin; Humans; Lidocaine | 2017 |
Superior Laryngeal Nerve Neuralgia: Case Series and Review of Anterior Neck Pain Syndromes.
Topics: Adult; Aged; Anesthetics, Local; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2019 |
Intravenous Lidocaine for Chronic Neuropathic Pain A Systematic Review Addressing Nursing Care.
Topics: Administration, Intravenous; Anesthetics, Local; Humans; Lidocaine; Neuralgia; Nursing Care | 2020 |
Topical medications as treatment of neuropathic orofacial pain.
Topics: Administration, Cutaneous; Capsaicin; Cyclooxygenase Inhibitors; Diclofenac; Facial Pain; Humans; Li | 2013 |
Topical therapies in the management of chronic pain.
Topics: Administration, Cutaneous; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; C | 2013 |
[Localized neuropathic pain--5% lidocaine medicated patch as a first-line treatment and as add-on therapy: literature review and personal experience].
Topics: Adult; Aged; Algorithms; Anesthetics, Local; Female; Humans; Lidocaine; Male; Middle Aged; Neuralgia | 2014 |
Topical lidocaine for neuropathic pain in adults.
Topics: Adult; Anesthetics, Local; Humans; Lidocaine; Neuralgia; Neuralgia, Postherpetic; Pain, Postoperativ | 2014 |
The in vitro mechanisms and in vivo efficacy of intravenous lidocaine on the neuroinflammatory response in acute and chronic pain.
Topics: Acute Pain; Administration, Intravenous; Anesthetics, Local; Animals; Calcium Channels; Chronic Pain | 2016 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
[Mechanisms of the development of neuropathic pain and its treatment].
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Calcium Channel Block | 2008 |
Treatment of neuropathic pain: an overview of recent guidelines.
Topics: Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents; Canada; Cyclohexa | 2009 |
Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review.
Topics: Analgesics; Anesthetics, Local; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Humans; Lidocaine | 2010 |
Trigeminal neuropathic pain in a patient with progressive facial hemiatrophy (parry-romberg syndrome).
Topics: Adult; Anesthetics, Local; Facial Hemiatrophy; Female; Follow-Up Studies; Humans; Lidocaine; Magneti | 2011 |
Pathophysiology of primary burning mouth syndrome.
Topics: Anesthetics, Local; Burning Mouth Syndrome; Clonazepam; Female; Functional Neuroimaging; Humans; Lid | 2012 |
Topical pain management with the 5% lidocaine medicated plaster--a review.
Topics: Administration, Topical; Anesthetics, Local; Bandages, Hydrocolloid; Humans; Lidocaine; Neuralgia; N | 2012 |
Management strategies for the treatment of neuropathic pain in the elderly.
Topics: Aged; Analgesics, Opioid; Anesthetics, Local; Anticonvulsants; Antidepressive Agents; Capsaicin; Cog | 2002 |
Treatment and prevention of postherpetic neuralgia.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combina | 2003 |
Lidocaine patch 5%.
Topics: Administration, Cutaneous; Anesthetics, Local; Diabetic Neuropathies; Drug Administration Schedule; | 2003 |
Diagnosis and management of neuropathic pain: a balanced approach to treatment.
Topics: Acetates; Amines; Antidepressive Agents; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; g | 2003 |
Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia.
Topics: Administration, Cutaneous; Anesthetics, Local; Herpes Zoster; Humans; Lidocaine; Neuralgia; Randomiz | 2004 |
Patching pain with lidocaine: new uses for the lidocaine 5% patch.
Topics: Administration, Cutaneous; Anesthetics, Local; Back Pain; Humans; Lidocaine; Neuralgia; Osteoarthrit | 2004 |
Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology.
Topics: Acupuncture Analgesia; Administration, Cutaneous; Amines; Analgesics; Analgesics, Opioid; Anti-Infla | 2004 |
Analgesic therapy in postherpetic neuralgia: a quantitative systematic review.
Topics: Analgesics; Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Herpe | 2005 |
Systemic lidocaine or mexiletine for neuropathic pain.
Topics: Administration, Oral; Anesthetics; Evidence-Based Medicine; Humans; Infusions, Intravenous; Lidocain | 2006 |
Systemic lidocaine for neuropathic pain relief.
Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel | 2000 |
Systemic lidocaine for neuropathic pain relief.
Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel | 2000 |
Systemic lidocaine for neuropathic pain relief.
Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel | 2000 |
Systemic lidocaine for neuropathic pain relief.
Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel | 2000 |
New analgesics for neuropathic pain: the lidocaine patch.
Topics: Administration, Cutaneous; Anesthetics, Local; Humans; Lidocaine; Neuralgia | 2000 |
[Diagnosis and assessment of pain].
Topics: Barbiturates; Humans; Ketamine; Lidocaine; Morphine; Neuralgia; Pain Measurement; Phentolamine | 2001 |
Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain.
Topics: Anesthetics, Local; Animals; Humans; Lidocaine; Neuralgia; Sodium Channels | 2002 |
59 trials available for lidocaine and Nerve Pain
| Article | Year |
|---|---|
Prediction of Individual Analgesic Response to Intravenous Lidocaine in Painful Diabetic Peripheral Neuropathy: A Randomized, Placebo-controlled, Crossover Trial.
Topics: Analgesics; Anesthetics, Local; Cross-Over Studies; Diabetes Mellitus; Diabetic Neuropathies; Double | 2021 |
A randomised placebo-controlled clinical trial on the efficacy of local lidocaine injections and oral citalopram for the treatment of complex regional pain syndrome.
Topics: Anesthetics, Local; Citalopram; Complex Regional Pain Syndromes; Double-Blind Method; Humans; Lidoca | 2022 |
Clinical Efficacy of Pulsed Radiofrequency Combined with Intravenous Lidocaine Infusion in the Treatment of Subacute Herpes Zoster Neuralgia.
Topics: Analgesics; Calcitonin Gene-Related Peptide; Herpes Zoster; Humans; Infusions, Intravenous; Interleu | 2022 |
Lidocaine for Neuropathic Cancer Pain (LiCPain): study protocol for a mixed-methods pilot study.
Topics: Cancer Pain; Clinical Trials, Phase II as Topic; Humans; Lidocaine; Neoplasms; Neuralgia; Pilot Proj | 2023 |
Considerations on the Obstacles That Lead to Slow Recruitment in a Pain Management Clinical Trial: Experiences from the Belgian PELICAN (PrEgabalin Lidocaine Capsaicin Neuropathic Pain) Pragmatic Study.
Topics: Belgium; Capsaicin; Humans; Lidocaine; Neuralgia; Pain Management; Pilot Projects; Pregabalin; Quali | 2023 |
Effect of piriformis injection on neuropathic pain.
Topics: Anesthetics, Local; Anti-Inflammatory Agents; Betamethasone; Drug Combinations; Female; Humans; Inje | 2019 |
Efficacy of the topical 5% lidocaine medicated plaster in the treatment of chronic post-thoracotomy neuropathic pain.
Topics: Administration, Topical; Adult; Aged; Female; Humans; Lidocaine; Male; Middle Aged; Neuralgia; Pain | 2017 |
The GroinPain Trial: A Randomized Controlled Trial of Injection Therapy Versus Neurectomy for Postherniorraphy Inguinal Neuralgia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Anesthetics, Local; Denervation; Drug Combin | 2018 |
Efficacy and Tolerance of Lidocaine 5% Patches in Neuropathic Pain and Pain Related to Vaso-occlusive Sickle Cell Crises in Children: A Prospective Multicenter Clinical Study.
Topics: Administration, Cutaneous; Adolescent; Adult; Anemia, Sickle Cell; Anesthetics, Local; Child; Female | 2018 |
Efficacy and Safety of Lidocaine Infusion Treatment for Neuropathic Pain: A Randomized, Double-Blind, and Placebo-Controlled Study.
Topics: Aged; Anesthetics, Local; Double-Blind Method; Female; Humans; Infusions, Intravenous; Lidocaine; Ma | 2018 |
Efficacy and Safety of Lidocaine Infusion Treatment for Neuropathic Pain: A Randomized, Double-Blind, and Placebo-Controlled Study.
Topics: Aged; Anesthetics, Local; Double-Blind Method; Female; Humans; Infusions, Intravenous; Lidocaine; Ma | 2018 |
Efficacy and Safety of Lidocaine Infusion Treatment for Neuropathic Pain: A Randomized, Double-Blind, and Placebo-Controlled Study.
Topics: Aged; Anesthetics, Local; Double-Blind Method; Female; Humans; Infusions, Intravenous; Lidocaine; Ma | 2018 |
Efficacy and Safety of Lidocaine Infusion Treatment for Neuropathic Pain: A Randomized, Double-Blind, and Placebo-Controlled Study.
Topics: Aged; Anesthetics, Local; Double-Blind Method; Female; Humans; Infusions, Intravenous; Lidocaine; Ma | 2018 |
Lidocaine medicated plaster, an additional potential treatment option for localized post-surgical neuropathic pain: efficacy and safety results of a randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Lidocaine; Male; Mi | 2019 |
Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial.
Topics: Adult; Aged; Analgesics; Anesthetics, Local; Breast Neoplasms; Double-Blind Method; Female; Humans; | 2019 |
Effectiveness and safety of 5% lidocaine-medicated plaster on localized neuropathic pain after knee surgery: a randomized, double-blind controlled trial.
Topics: Aged; Anesthetics, Local; Arthroplasty, Replacement, Knee; Double-Blind Method; Female; Humans; Hype | 2019 |
A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia.
Topics: Aged; Aged, 80 and over; Capsaicin; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Ma | 2013 |
[Intraosseous blocks in the treatment of symmetrical distal diabetic polyneuropathy].
Topics: Aged; Amitriptyline; Analgesics, Non-Narcotic; Anesthetics, Local; Diabetic Neuropathies; Female; Fo | 2013 |
A pain model with a neuropathic somatosensory lesion: Morton neuroma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthetics, Local; Cold Temperature; Cross-Over Studies | 2013 |
Thiamine, cobalamin, locally injected alone or combination for herpetic itching: a single-center randomized controlled trial.
Topics: Activities of Daily Living; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Female; Her | 2014 |
Lidocaine 5 % patches as an effective short-term co-analgesic in cancer pain. Preliminary results.
Topics: Anesthetics, Local; Breast Neoplasms; Cicatrix; Female; Follow-Up Studies; Humans; Lidocaine; Male; | 2013 |
Tolerability of the capsaicin 8% patch following pretreatment with lidocaine or tramadol in patients with peripheral neuropathic pain: a multicentre, randomized, assessor-blinded study.
Topics: Adult; Aged; Analgesics, Opioid; Anesthetics, Local; Capsaicin; Female; Humans; Lidocaine; Male; Mid | 2014 |
Efficacy of lidocaine in patients receiving palliative care with opioid-refractory cancer pain with a neuropathic component: study protocol for a randomized controlled study.
Topics: Administration, Intravenous; Anesthetics, Local; Clinical Protocols; Double-Blind Method; Drug Resis | 2014 |
Cervical transforaminal epidural block using low-dose local anesthetic: a prospective, randomized, double-blind study.
Topics: Analgesia, Epidural; Anesthetics, Local; Cervical Vertebrae; Dexamethasone; Dose-Response Relationsh | 2015 |
Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study.
Topics: Adult; Aged; Anesthetics, Local; Cross-Over Studies; Double-Blind Method; Female; Humans; Hyperalges | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness.
Topics: Adult; Anesthetics, Local; Bupivacaine; Delayed-Action Preparations; Double-Blind Method; Drug Thera | 2015 |
Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB).
Topics: Administration, Cutaneous; Aged; Anesthetics, Local; Cross-Over Studies; Double-Blind Method; Female | 2009 |
Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB).
Topics: Administration, Cutaneous; Aged; Anesthetics, Local; Cross-Over Studies; Double-Blind Method; Female | 2009 |
Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB).
Topics: Administration, Cutaneous; Aged; Anesthetics, Local; Cross-Over Studies; Double-Blind Method; Female | 2009 |
Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB).
Topics: Administration, Cutaneous; Aged; Anesthetics, Local; Cross-Over Studies; Double-Blind Method; Female | 2009 |
The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study.
Topics: Adult; Aged; Analgesia; Anesthetics, Local; Chronic Disease; Cross-Over Studies; Double-Blind Method | 2009 |
Clinical study of low back pain and radicular pain pathways by using l2 spinal nerve root infiltration: a randomized, controlled, clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Dexamet | 2009 |
Management of neuropathic pain after surgical and non-surgical trauma with lidocaine 5% patches: study of 40 consecutive cases.
Topics: Administration, Cutaneous; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Lidocaine; | 2009 |
Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Anesthetics, Local; Data Collection; Eryt | 2010 |
Pain quality predicts lidocaine analgesia among patients with suspected neuropathic pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthetics, Local; Cohort Studies; Humans; Infusions, I | 2010 |
[Lidocaine patch for therapy of neuropathic and non-neuropathic pain. A clinical case series of 87 patients].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anesthetics, Local; Female; Humans; Lidocai | 2010 |
Antihyperalgesic efficacy of 5% lidocaine medicated plaster in capsaicin and sunburn pain models--two randomized, double-blinded, placebo-controlled crossover trials in healthy volunteers.
Topics: Administration, Cutaneous; Adult; Anesthetics, Local; Capsaicin; Cross-Over Studies; Dose-Response R | 2011 |
Management of neuropathic pain with methylprednisolone at the site of nerve injury.
Topics: Anesthetics, Local; Double-Blind Method; Female; Humans; Lidocaine; Male; Methylprednisolone; Middle | 2012 |
The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain.
Topics: Adult; Analgesics; Anesthetics, Local; Cross-Over Studies; Double-Blind Method; Female; Humans; Infu | 2003 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.
Topics: Acetates; Activities of Daily Living; Aged; Aged, 80 and over; Amines; Analgesics; Anesthetics, Loca | 2003 |
Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale.
Topics: Administration, Cutaneous; Aged; Anesthetics, Local; Chronic Disease; Diabetic Neuropathies; Female; | 2004 |
Analgesic effect of intravenous ATP on postherpetic neuralgia in comparison with responses to intravenous ketamine and lidocaine.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Analgesics; Anesthetics, Dissociative; Anest | 2005 |
Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale.
Topics: Administration, Cutaneous; Adult; Aged; Analysis of Variance; Anesthetics, Local; Clinical Trials as | 2005 |
Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Female; | 2005 |
Dental impaction pain model as a potential tool to evaluate drugs with efficacy in neuropathic pain.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthetics, Local; | 2006 |
Symptom profiles differ in patients with neuropathic versus non-neuropathic pain.
Topics: Administration, Topical; Adult; Aged; Anesthetics, Local; Diabetic Neuropathies; Female; Humans; Lid | 2007 |
A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain.
Topics: Anesthetics, Local; Cross-Over Studies; Double-Blind Method; Female; Humans; Injections, Intravenous | 1992 |
[The efficacy of intravenous lidocaine on various types of neuropathic pain].
Topics: Aged; Female; Humans; Infusions, Intravenous; Lidocaine; Male; Middle Aged; Neuralgia | 1995 |
Topical lidocaine gel relieves postherpetic neuralgia.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Blood Pressure; Double-Blind Method; Erythema; F | 1995 |
Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study.
Topics: Administration, Oral; Adult; Aged; Anesthetics, Local; Anti-Arrhythmia Agents; Double-Blind Method; | 1996 |
Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Female; | 1996 |
Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Female; | 1996 |
Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Female; | 1996 |
Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anesthetics, Local; Double-Blind Method; Female; | 1996 |
Reversal of hypoaesthesia by nerve block, or placebo: a psychologically mediated sign in chronic pseudoneuropathic pain patients.
Topics: Adult; Causalgia; Diagnosis, Differential; Female; Humans; Hypesthesia; Lidocaine; Male; Middle Aged | 1998 |
[Lidocaine tape (Penles--a dressing tape based on 60% lidocaine--) reduces the pain of postherpetic neuralgia].
Topics: Aged; Aged, 80 and over; Anesthetics, Local; Female; Herpes Zoster; Humans; Lidocaine; Male; Neuralg | 1998 |
Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Anesthetics, Local; Cross-Over Studies; Double-Bli | 1999 |
Topical EMLA pre-treatment fails to decrease the pain induced by 1% topical capsaicin.
Topics: Administration, Topical; Adult; Anesthetics, Local; Capsaicin; Drug Tolerance; Female; Humans; Lidoc | 1999 |
Effects of single and repeated applications of a eutectic mixture of local anaesthetics (EMLA) cream on spontaneous and evoked pain in post-herpetic neuralgia.
Topics: Aged; Aged, 80 and over; Anesthetics, Combined; Anesthetics, Local; Female; Herpesviridae Infections | 1999 |
A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia.
Topics: Aged; Anesthetics, Local; Cross-Over Studies; Double-Blind Method; Female; Herpesviridae Infections; | 1999 |
Topical acetylsalicylic acid versus lidocaine for postherpetic neuralgia: results of a double-blind comparative clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Anesthetics, Local; Aspirin; Double-Blind Method; Female | 1999 |
A comparison of minidose lidocaine-fentanyl and conventional-dose lidocaine spinal anesthesia.
Topics: Adjuvants, Anesthesia; Adult; Anesthesia Recovery Period; Anesthesia, Spinal; Anesthetics, Local; Ar | 2000 |
Intrathecal methylprednisolone for intractable postherpetic neuralgia.
Topics: Aged; Anesthetics, Local; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Diclofe | 2000 |
[Relief of subacute herpetic pain and postherpetic neuralgia with repeated application of 10% lidocaine cream].
Topics: Aged; Anesthetics, Local; Female; Herpes Zoster; Humans; Lidocaine; Male; Middle Aged; Neuralgia; Oi | 2000 |
Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster.
Topics: Acute Disease; Administration, Cutaneous; Administration, Topical; Adult; Aged; Aged, 80 and over; A | 2002 |
Lidocaine test in neuralgia.
Topics: Adolescent; Adult; Aged; Blood Pressure; Chronic Disease; Electrocardiography; Female; Humans; Lidoc | 1992 |
Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia.
Topics: Aged; Double-Blind Method; Female; Herpes Zoster; Humans; Injections, Intravenous; Lidocaine; Male; | 1991 |
170 other studies available for lidocaine and Nerve Pain
| Article | Year |
|---|---|
Nursing Care During Lidocaine Infusion Therapy for Chronic Pain.
Topics: Anesthetics, Local; Chronic Pain; Humans; Infusions, Intravenous; Lidocaine; Neuralgia; Pain Measure | 2022 |
Localized peripheral neuropathic pain: topical treatment with lidocaine 700 mg medicated plaster in routine clinical practice.
Topics: Anesthetics, Local; Cohort Studies; Humans; Lidocaine; Neuralgia; Neuralgia, Postherpetic; Quality o | 2022 |
Nerve injury induces transient locus coeruleus activation over time: role of the locus coeruleus-dorsal reticular nucleus pathway.
Topics: Animals; Chronic Pain; Hyperalgesia; Lidocaine; Locus Coeruleus; Male; Neuralgia; Rats; Rats, Spragu | 2022 |
Trigeminal neuropathic pain reduces 50-kHz ultrasonic vocalizations in rats, which are restored by analgesic drugs.
Topics: Analgesics; Animals; Carbamazepine; Hyperalgesia; Lidocaine; Male; Midazolam; Neuralgia; Rats; Trige | 2022 |
Lidocaine for dinutuximab-associated pain? A multicenter retrospective observational cohort study.
Topics: Antibodies, Monoclonal; Child; Humans; Lidocaine; Morphine Derivatives; Neuralgia; Neuroblastoma; Re | 2022 |
Postsurgical neuropathic pain: lidocaine 700 mg medicated plaster or oral treatments in clinical practice.
Topics: Anesthetics, Local; Cohort Studies; Humans; Lidocaine; Neuralgia; Neuralgia, Postherpetic; Quality o | 2022 |
Local hyperexcitability of C-nociceptors may predict responsiveness to topical lidocaine in neuropathic pain.
Topics: Analgesics; Anesthetics, Local; Humans; Lidocaine; Neuralgia; Nociceptors; Pain Measurement | 2022 |
[Efficacy analysis of lidocaine plaster combined with gabapentin in the treatment of herpes zoster neuralgia].
Topics: Aged; Female; Gabapentin; Herpes Zoster; Humans; Lidocaine; Male; Middle Aged; Neuralgia; Quality of | 2022 |
Effect of neuropathic pain on sphenopalatine ganglion block responses in persistent idiopathic facial pain.
Topics: Adult; Chronic Pain; Facial Pain; Humans; Lidocaine; Middle Aged; Neuralgia; Sphenopalatine Ganglion | 2023 |
Effect of neuropathic pain on sphenopalatine ganglion block responses in persistent idiopathic facial pain.
Topics: Adult; Chronic Pain; Facial Pain; Humans; Lidocaine; Middle Aged; Neuralgia; Sphenopalatine Ganglion | 2023 |
Effect of neuropathic pain on sphenopalatine ganglion block responses in persistent idiopathic facial pain.
Topics: Adult; Chronic Pain; Facial Pain; Humans; Lidocaine; Middle Aged; Neuralgia; Sphenopalatine Ganglion | 2023 |
Effect of neuropathic pain on sphenopalatine ganglion block responses in persistent idiopathic facial pain.
Topics: Adult; Chronic Pain; Facial Pain; Humans; Lidocaine; Middle Aged; Neuralgia; Sphenopalatine Ganglion | 2023 |
Effect of neuropathic pain on sphenopalatine ganglion block responses in persistent idiopathic facial pain.
Topics: Adult; Chronic Pain; Facial Pain; Humans; Lidocaine; Middle Aged; Neuralgia; Sphenopalatine Ganglion | 2023 |
Effect of neuropathic pain on sphenopalatine ganglion block responses in persistent idiopathic facial pain.
Topics: Adult; Chronic Pain; Facial Pain; Humans; Lidocaine; Middle Aged; Neuralgia; Sphenopalatine Ganglion | 2023 |
Effect of neuropathic pain on sphenopalatine ganglion block responses in persistent idiopathic facial pain.
Topics: Adult; Chronic Pain; Facial Pain; Humans; Lidocaine; Middle Aged; Neuralgia; Sphenopalatine Ganglion | 2023 |
Effect of neuropathic pain on sphenopalatine ganglion block responses in persistent idiopathic facial pain.
Topics: Adult; Chronic Pain; Facial Pain; Humans; Lidocaine; Middle Aged; Neuralgia; Sphenopalatine Ganglion | 2023 |
Effect of neuropathic pain on sphenopalatine ganglion block responses in persistent idiopathic facial pain.
Topics: Adult; Chronic Pain; Facial Pain; Humans; Lidocaine; Middle Aged; Neuralgia; Sphenopalatine Ganglion | 2023 |
Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment.
Topics: Analgesics; Analgesics, Opioid; Humans; Lidocaine; Neoplasms; Neuralgia; Pain Measurement; Prospecti | 2023 |
[Long-term effectiveness of topical analgesics].
Topics: Administration, Topical; Analgesics; Botulinum Toxins, Type A; Capsaicin; Female; Humans; Lidocaine; | 2020 |
Using transdermal patches to treat neuropathic pain.
Topics: Anesthetics, Local; Capsaicin; Humans; Lidocaine; Neuralgia; Patient Education as Topic; Transdermal | 2020 |
Lidocaine Alleviates Neuropathic Pain and Neuroinflammation by Inhibiting HMGB1 Expression to Mediate MIP-1α/CCR1 Pathway.
Topics: Anesthetics, Local; Animals; Chemokine CCL3; Female; HMGB1 Protein; Inflammation; Lidocaine; Neuralg | 2021 |
Acute effect of sphenopalatine ganglion block with lidocaine in a patient with SUNCT.
Topics: Headache; Humans; Lidocaine; Neuralgia; Sphenopalatine Ganglion Block; SUNCT Syndrome; Treatment Out | 2020 |
Effectiveness and safety of lidocaine patch 5% to treat herpes zoster acute neuralgia and to prevent postherpetic neuralgia.
Topics: Herpes Zoster; Humans; Lidocaine; Neuralgia; Neuralgia, Postherpetic | 2021 |
Lidocaine activates autophagy of astrocytes and ameliorates chronic constriction injury-induced neuropathic pain.
Topics: Anesthetics, Local; Animals; Astrocytes; Autophagy; Cell Proliferation; Cells, Cultured; Constrictio | 2021 |
Oral appliances in the management of neuropathic orofacial pain: A retrospective case series.
Topics: Facial Pain; Humans; Lidocaine; Neuralgia; Retrospective Studies; Trigeminal Neuralgia | 2022 |
Lidocaine Continuous Subcutaneous Infusion for Neuropathic Pain in Hospice Patients: Safety and Efficacy.
Topics: Analgesics, Opioid; Hospices; Humans; Infusions, Subcutaneous; Lidocaine; Neuralgia | 2021 |
Treatment of great auricular neuralgia with real-time ultrasound-guided great auricular nerve block: A case report and review of the literature.
Topics: Anesthetics, Local; Anti-Inflammatory Agents; Ear Auricle; Humans; Lidocaine; Male; Nerve Block; Neu | 2017 |
Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe - the role of the lidocaine 5% medicated plaster.
Topics: Aged; Aged, 80 and over; Amines; Anesthetics, Local; Cyclohexanecarboxylic Acids; Duloxetine Hydroch | 2017 |
Cardioprotection induced in a mouse model of neuropathic pain via anterior nucleus of paraventricular thalamus.
Topics: Animals; Butadienes; Chronic Pain; Disease Models, Animal; Enzyme Inhibitors; Ganglionic Blockers; H | 2017 |
Efficacy and safety of 5% lidocaine-medicated plasters in localized pain with neuropathic and/or inflammatory characteristics: an observational, real-world study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthetics, Local; Female; Humans; Hyperalgesia; Lidoca | 2017 |
Dopaminergic tone does not influence pain levels during placebo interventions in patients with chronic neuropathic pain.
Topics: Adult; Aged; Anesthetics, Local; Carbidopa; Chronic Pain; Dopamine; Dopamine Agents; Drug Combinatio | 2018 |
A Case Report of Refractory Notalgia Paresthetica Treated with Lidocaine Infusions.
Topics: Anesthetics, Local; Epidural Abscess; Female; Humans; Infusions, Intravenous; Lidocaine; Middle Aged | 2017 |
Arachnidism by Segestria bavarica with severe neuropathic pain successfully treated with lidocaine 5% plaster.
Topics: Anesthetics, Local; Animals; Arm Injuries; Female; Follow-Up Studies; Humans; Lidocaine; Middle Aged | 2018 |
Does conditioned pain modulation predict the magnitude of placebo effects in patients with neuropathic pain?
Topics: Adult; Aged; Conditioning, Psychological; Female; Humans; Lidocaine; Male; Middle Aged; Neuralgia; P | 2018 |
Oxidative Stress in the Amygdala Contributes to Neuropathic Pain.
Topics: Amygdala; Animals; Carbenoxolone; Conditioning, Psychological; Cyclic N-Oxides; Internal Capsule; Li | 2018 |
Pathophysiological mechanisms of neuropathic pain: comparison of sensory phenotypes in patients and human surrogate pain models.
Topics: Adult; Aged; Algorithms; Capsaicin; Female; Healthy Volunteers; Humans; Hyperalgesia; Lidocaine; Mal | 2018 |
Metabotropic glutamate receptor subtype 7 in the dorsal striatum oppositely modulates pain in sham and neuropathic rats.
Topics: Animals; Benzhydryl Compounds; Benzoxazoles; Corpus Striatum; Glutamic Acid; Hyperalgesia; Lidocaine | 2018 |
How central is central poststroke pain? The role of afferent input in poststroke neuropathic pain: a prospective, open-label pilot study.
Topics: Adult; Anesthetics, Local; Central Nervous System Sensitization; Female; Humans; Lidocaine; Male; Mi | 2018 |
Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy.
Topics: Aged; Analgesics; Anesthetics, Local; Drug Evaluation; Drug Resistance; Drug Therapy, Combination; E | 2018 |
Pain in the hand caused by a previously undescribed mechanism with possible relevance for understanding regional pain.
Topics: Acupuncture Points; Adult; Anesthetics, Local; Bupivacaine; Female; Hand; Humans; Injections, Intrav | 2018 |
Predictive value of a diagnostic block in focal nerve injury with neuropathic pain when surgery is considered.
Topics: Adolescent; Adult; Aged; Algorithms; Anesthetics, Local; Chronic Pain; Female; Humans; Lidocaine; Ma | 2018 |
An add-on therapy for neuropathic pain: Infiltration block with diclofenac sodium and lidocaine through the hypertrophic scar tissue.
Topics: Adult; Aged; Anesthetics, Local; Cicatrix, Hypertrophic; Diclofenac; Female; Humans; Injections; Lid | 2019 |
Suppression of neuropathic pain by selective silencing of dorsal root ganglion ectopia using nonblocking concentrations of lidocaine.
Topics: Anesthetics, Local; Animals; Ganglia, Spinal; Infusion Pumps; Lidocaine; Male; Neuralgia; Pain Measu | 2019 |
Lidocaine Potentiates SOCS3 to Attenuate Inflammation in Microglia and Suppress Neuropathic Pain.
Topics: Animals; Calcium-Binding Proteins; Cell Line; Chronic Disease; Constriction, Pathologic; Cyclic AMP | 2019 |
Descending facilitation maintains long-term spontaneous neuropathic pain.
Topics: Afferent Pathways; Anesthetics, Local; Animals; Benzodiazepines; Conditioning, Operant; Disease Mode | 2013 |
Topical medications for the effective management of neuropathic orofacial pain.
Topics: Administration, Topical; Amines; Analgesics, Non-Narcotic; Anesthetics, Local; Anti-Inflammatory Age | 2013 |
Management options in neuropathic pain.
Topics: Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents, Tricyclic; Calcium Channel Blockers; | 2012 |
Osteoarthritis pain has a significant neuropathic component: an exploratory in vivo patient model.
Topics: Adult; Aged; Anesthetics, Local; Arthralgia; Female; Humans; Infusions, Intravenous; Lidocaine; Male | 2014 |
Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary?
Topics: Analgesics; Analgesics, Opioid; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Capsaic | 2014 |
[Experience with 5% lidocaine medicated plaster in the treatment of localized neuropathic pain].
Topics: Administration, Cutaneous; Aged; Anesthetics, Local; Calcium Sulfate; Drug Carriers; Female; Humans; | 2013 |
Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy.
Topics: Adolescent; Adult; Afferent Pathways; Aged; Aged, 80 and over; Anesthetics, Local; Central Nervous S | 2014 |
Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy.
Topics: Adolescent; Adult; Afferent Pathways; Aged; Aged, 80 and over; Anesthetics, Local; Central Nervous S | 2014 |
Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy.
Topics: Adolescent; Adult; Afferent Pathways; Aged; Aged, 80 and over; Anesthetics, Local; Central Nervous S | 2014 |
Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy.
Topics: Adolescent; Adult; Afferent Pathways; Aged; Aged, 80 and over; Anesthetics, Local; Central Nervous S | 2014 |
Peripheral nervous system origin of phantom limb pain.
Topics: Adult; Aged; Anesthesia, Spinal; Anesthetics, Local; Female; Ganglia, Spinal; Humans; Injections, Sp | 2014 |
Use of 5% lidocaine medicated plasters for the treatment of pain in routine hospital practice: patient reported pain, functioning and satisfaction.
Topics: Administration, Cutaneous; Anesthetics, Local; Dosage Forms; Health Care Surveys; Hospitals, Teachin | 2014 |
Effect of 5% lidocaine medicated plaster on pain intensity and paroxysms in classical trigeminal neuralgia.
Topics: Aged; Aged, 80 and over; Anesthetics, Local; Female; Humans; Lidocaine; Neuralgia; Trigeminal Neural | 2014 |
Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions.
Topics: Adult; Aged; Anesthetics, Local; Capsaicin; Emotions; Female; Humans; Lidocaine; Male; Middle Aged; | 2014 |
[Topical pharmacologic approach with 5% lidocaine medicated plaster in the treatment of localized neuropathic pain].
Topics: Administration, Cutaneous; Adult; Aged; Anesthetics, Local; Blood Vessel Prosthesis Implantation; Br | 2014 |
Descending mechanisms activated by the anterior pretectal nucleus initiate but do not maintain neuropathic pain in rats.
Topics: Anesthetics, Local; Animals; Constriction, Pathologic; Hyperalgesia; Lidocaine; Male; Methysergide; | 2015 |
Intravenous lidocaine for neuropathic pain: a retrospective analysis of tolerability and efficacy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Dizziness; Female; Humans; Infusions, Intravenous | 2015 |
A simplified CT-guided approach for greater occipital nerve infiltration in the management of occipital neuralgia.
Topics: Anesthesia, Local; Anesthetics, Local; Female; Humans; Injections, Subcutaneous; Lidocaine; Male; Mi | 2015 |
Prolonged Suppression of Neuropathic Pain by Sequential Delivery of Lidocaine and Thalidomide Drugs Using PEGylated Graphene Oxide.
Topics: Anesthetics, Local; Animals; Cells, Cultured; Cytokines; Delayed-Action Preparations; Graphite; Huma | 2015 |
Mechanism-based therapy for neuropathic pain-a concept in danger?
Topics: Anesthetics, Local; Female; Humans; Lidocaine; Male; Neuralgia; Pain Threshold; Phenotype | 2015 |
Sciatic Nerve Intrafascicular Lidocaine Injection-induced Peripheral Neuropathic Pain: Alleviation by Systemic Minocycline Administration.
Topics: Activating Transcription Factor 3; Analysis of Variance; Anesthetics, Local; Animals; Anti-Bacterial | 2016 |
In Response to Letter to the Editor: Cervical Transforaminal with Low-Dose Local Anesthetic Is Not a Safeguard for Neurological Complications.
Topics: Analgesia, Epidural; Anesthetics, Local; Female; Humans; Lidocaine; Male; Neuralgia | 2016 |
Cervical Transforaminal with Low-Dose Local Anesthetic Is Not a Safeguard for Neurological Complications.
Topics: Analgesia, Epidural; Anesthetics, Local; Female; Humans; Lidocaine; Male; Neuralgia | 2016 |
Inhibition of mechanical allodynia in neuropathic pain by TLR5-mediated A-fiber blockade.
Topics: Adult; Aged; Anesthetics, Local; Animals; Antineoplastic Agents; Capsaicin; Diabetic Neuropathies; F | 2015 |
Targeting Toll-like receptors to treat chronic pain.
Topics: Anesthetics, Local; Animals; Chronic Pain; Flagellin; Humans; Hyperalgesia; Lidocaine; Mice; Nerve F | 2015 |
[Topical ambroxol for the treatment of neuropathic pain: A first clinical observation. German version].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Ambroxol; Capsaicin; Female; Humans; Lidoca | 2015 |
Pain: TLR5 opens the door to neuropathic-pain treatment.
Topics: Anesthetics, Local; Animals; Female; Flagellin; Ganglia, Spinal; Humans; Hyperalgesia; Lidocaine; Ma | 2015 |
A pharmacological treatment algorithm for localized neuropathic pain.
Topics: Algorithms; Analgesics; Anesthetics, Local; Humans; Lidocaine; Neuralgia | 2016 |
Central Sensitization and Neuropathic Features of Ongoing Pain in a Rat Model of Advanced Osteoarthritis.
Topics: Analgesics; Animals; Arthralgia; Central Nervous System Sensitization; Disease Models, Animal; Dose- | 2016 |
Lidocaine 5% Medicated Plaster for Spinal Neuropathic Pain.
Topics: Administration, Cutaneous; Aged; Anesthetics, Local; Decompression, Surgical; Humans; Lidocaine; Mal | 2016 |
Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients.
Topics: Adult; Aged; Anesthetics, Local; Female; Humans; Infusions, Intravenous; Lidocaine; Male; Middle Age | 2016 |
Lidocaine 5% medicated plaster for localized neuropathic pain in thoracic surgical patients.
Topics: Adult; Aged; Anesthetics, Local; Female; Humans; Lidocaine; Male; Middle Aged; Neuralgia; Retrospect | 2017 |
Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection.
Topics: Analgesics; Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response R | 2008 |
Parenteral lidocaine for neuropathic pain #180.
Topics: Anesthetics, Local; Humans; Infusions, Parenteral; Lidocaine; Neuralgia | 2009 |
Assessing Aδ fiber function with lidocaine using intraepidermal electrical stimulation.
Topics: Adult; Anesthetics, Local; Electric Stimulation; Electrodes; Electrodiagnosis; Epidermis; Female; Hu | 2010 |
Mexiletine suppresses nodal persistent sodium currents in sensory axons of patients with neuropathic pain.
Topics: Adult; Aged; Axons; Electric Conductivity; Electrophysiological Phenomena; Female; Humans; Lidocaine | 2010 |
A role for intravenous lidocaine in severe cancer-related neuropathic pain at the end-of-life.
Topics: Aged; Anesthetics, Local; Back Pain; Bone Neoplasms; Humans; Infusions, Intravenous; Kidney Neoplasm | 2010 |
Techniques of pudendal nerve block.
Topics: Adrenal Cortex Hormones; Anal Canal; Anesthetics, Local; Clitoris; Female; Genitalia, Female; Humans | 2010 |
[Types of topical treatment for peripheral neuropathic pain : Mechanism of action and indications].
Topics: Administration, Topical; Afferent Pathways; Analgesics; Anesthetics, Local; Antidepressive Agents; C | 2010 |
Lidocaine suppresses the increased extracellular signal-regulated kinase/cyclic AMP response element-binding protein pathway and pro-inflammatory cytokines in a neuropathic pain model of rats.
Topics: Anesthetics, Local; Animals; Cyclic AMP Response Element-Binding Protein; Cytokines; Disease Models, | 2011 |
Intrathecal lidocaine pretreatment attenuates immediate neuropathic pain by modulating Nav1.3 expression and decreasing spinal microglial activation.
Topics: Anesthetics, Local; Animals; Blotting, Western; Fluorescent Antibody Technique; Ganglia, Spinal; Imm | 2011 |
Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: a pilot study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Anesthetics, L | 2012 |
Comparison of actions of systemically and locally administrated local anaesthetics in diabetic rats with painful neuropathy.
Topics: Anesthetics, Local; Animals; Bupivacaine; Diabetes Mellitus, Experimental; Disease Models, Animal; F | 2013 |
Supraclavicular nerve entrapment syndrome.
Topics: Analgesics; Antirheumatic Agents; Brachial Plexus; Clavicle; Humans; Lidocaine; Male; Middle Aged; N | 2012 |
Genitofemoral and perineal neuralgia after transobturator midurethral sling.
Topics: Amides; Analgesics, Non-Narcotic; Anesthetics, Local; Autonomic Nerve Block; Carbamazepine; Female; | 2012 |
The prevalence and cost of unapproved uses of top-selling orphan drugs.
Topics: Benzhydryl Compounds; Cinacalcet; Costs and Cost Analysis; Drug Approval; Humans; Lidocaine; Modafin | 2012 |
Occipital nerve block is effective in craniofacial neuralgias but not in idiopathic persistent facial pain.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Anti-Inflammatory Agents; Dexamethasone; Facial | 2012 |
Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study.
Topics: Adult; Aged; Analgesics; Analgesics, Opioid; Anesthetics, Local; Anti-Inflammatory Agents, Non-Stero | 2012 |
Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain.
Topics: Analgesics; Anesthetics, Local; Child, Preschool; Fatal Outcome; Female; Humans; Infusions, Intraven | 2012 |
Refractory facial pain attributed to auriculotemporal neuralgia.
Topics: Adult; Anesthetics, Local; Facial Pain; Female; Humans; Lidocaine; Mandibular Nerve; Neuralgia | 2012 |
Intractable neuropathic pain in spinal intramedullary cavernoma treated successfully with a novel combination cream.
Topics: Capsaicin; Drug Combinations; Humans; Isosorbide Dinitrate; Lidocaine; Male; Middle Aged; Neuralgia; | 2012 |
Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anesthetics, Local; Bandages, Hydrocolloid; Chro | 2012 |
Differential effects of peripheral versus central coadministration of QX-314 and capsaicin on neuropathic pain in rats.
Topics: Anesthetics, Local; Animals; Antipruritics; Capsaicin; Disease Models, Animal; Drug Administration R | 2012 |
Expression of TRPV1 channels after nerve injury provides an essential delivery tool for neuropathic pain attenuation.
Topics: Anesthetics, Local; Animals; Capsaicin; Gene Expression; Hyperalgesia; Lidocaine; Male; Mandibular N | 2012 |
Treatment of acute and chronic focal neuropathic pain in cancer patients with lidocaine 5 % patches. A radiation and oncology department experience.
Topics: Acute Pain; Aged; Aged, 80 and over; Anesthetics, Local; Chronic Pain; Female; Humans; Lidocaine; Ma | 2013 |
5% lidocaine medicated plaster use in children with neuropathic pain from burn sequelae.
Topics: Administration, Cutaneous; Adolescent; Anesthetics, Local; Bandages; Burns; Child; Female; Humans; L | 2013 |
Effectiveness and safety of lidocaine patch 5%.
Topics: Administration, Topical; Anesthetics, Local; Herpesviridae Infections; Humans; Lidocaine; Neuralgia; | 2002 |
Lidocaine and methylprednisolone in management of herpes zoster and post-herpetic neuralgia.
Topics: Aged; Analgesia, Epidural; Anesthetics, Local; Anti-Inflammatory Agents; Female; Herpes Zoster; Huma | 2002 |
A comparison of the antinociceptive effects of voltage-activated Na+ channel blockers in two rat models of neuropathic pain.
Topics: Analgesics; Analysis of Variance; Anesthetics, Local; Animals; Disease Models, Animal; Dose-Response | 2003 |
More than 7 years of consistent neuropathic pain relief in geriatric patients.
Topics: Aged; Aged, 80 and over; Analgesics; Anesthetics, Local; Drug Therapy, Combination; Female; Humans; | 2003 |
Multiple phases of relief from experimental mechanical allodynia by systemic lidocaine: responses to early and late infusions.
Topics: Anesthetics, Local; Animals; Behavior, Animal; Functional Laterality; Hyperalgesia; Infusions, Intra | 2003 |
Patching up pain.
Topics: Administration, Cutaneous; Humans; Lidocaine; Neuralgia | 2003 |
[Xylocaine as a therapeutic drug in the treatment of atypical neuralgia].
Topics: Anesthetics; Anesthetics, Local; Humans; Lidocaine; Neuralgia | 1953 |
[Value of xylocaine in therapy of atypical neuralgias].
Topics: Anesthetics; Anesthetics, Local; Disease; Face; Humans; Lidocaine; Neuralgia | 1953 |
TRAUMATIC NASAL NEURALGIA AND ITS TREATMENT.
Topics: Facial Injuries; Humans; Lidocaine; Neuralgia; Nose; Ophthalmic Nerve; Trigeminal Neuralgia | 1963 |
Key role of the dorsal root ganglion in neuropathic tactile hypersensibility.
Topics: Anesthetics, Local; Animals; Disease Models, Animal; Ganglia, Spinal; Hindlimb; Hyperesthesia; Lidoc | 2004 |
Decreasing sympathetic sprouting in pathologic sensory ganglia: a new mechanism for treating neuropathic pain using lidocaine.
Topics: Adrenergic Fibers; Anesthetics, Local; Animals; Cell Count; Functional Laterality; Ganglia, Sensory; | 2004 |
Conquering peripheral neuropathic pain.
Topics: Acetates; Amines; Analgesics; Anesthetics, Local; Antidepressive Agents, Tricyclic; Cyclohexanecarbo | 2004 |
Pharmacological characterisation of the rat brachial plexus avulsion model of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Analysis of Variance; Animals; Brachial Plexus; Brachial Plexus Neurop | 2004 |
[Not only diabetics have experienced the pain... distressing neuralgia].
Topics: Acyclovir; Aged; Analgesics, Opioid; Anesthesia, Local; Anticonvulsants; Antidepressive Agents, Tric | 2004 |
Introduction: chronic pain studies of the lidocaine patch 5% using the Neuropathic Pain Scale.
Topics: Administration, Cutaneous; Anesthetics, Local; Chronic Disease; Humans; Lidocaine; Neuralgia; Pain; | 2004 |
Conclusions: chronic pain studies of lidocaine patch 5% using the Neuropathic Pain Scale.
Topics: Administration, Cutaneous; Anesthetics, Local; Chronic Disease; Clinical Trials as Topic; Humans; Li | 2004 |
Lidocaine intoxication at very small doses in terminally ill cancer patients.
Topics: Aged; Aged, 80 and over; Anesthetics, Local; Disorders of Excessive Somnolence; Dose-Response Relati | 2005 |
Tolerability of treatments for postherpetic neuralgia.
Topics: Administration, Cutaneous; Anesthetics, Local; Clinical Trials as Topic; Herpes Zoster; Humans; Lido | 2005 |
Cervicogenic headache in patients with presumed migraine: missed diagnosis or misdiagnosis?
Topics: Adult; Aged; Anesthetics, Local; Bupivacaine; Cervical Plexus; Cervical Vertebrae; Chronic Disease; | 2005 |
Skin biopsy and quantitative sensory testing do not predict response to lidocaine patch in painful neuropathies.
Topics: Aged; Anesthetics, Local; Biopsy; Cohort Studies; Epidermis; Female; Humans; Leg; Lidocaine; Male; M | 2006 |
Non-hypothalamic cluster headache: the role of the greater occipital nerve in cluster headache pathogenesis.
Topics: Afferent Pathways; Anesthetics, Local; Anti-Inflammatory Agents; Anticonvulsants; Circadian Rhythm; | 2005 |
The lidocaine patch: a useful addition to the pain clinic armamentarium.
Topics: Administration, Cutaneous; Adult; Anesthetics, Local; Chronic Disease; Female; Humans; Lidocaine; Ne | 2006 |
Nerve-stimulator-guided repeated pudendal nerve block for treatment of pudendal neuralgia.
Topics: Analgesics; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Clonidine; Electric Stimulation; Ep | 2006 |
Comparative effects of lidocaine and tramadol on injured peripheral nerves.
Topics: 4-Aminopyridine; Action Potentials; Analgesics, Opioid; Anesthetics, Local; Animals; Dose-Response R | 2006 |
Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat.
Topics: Analysis of Variance; Anesthetics, Local; Animals; Behavior, Animal; Calcitonin Gene-Related Peptide | 2007 |
Acute scrotal pain from idiopathic ilioinguinal neuropathy: diagnosis and treatment with EMG-guided nerve block.
Topics: Adult; Electrodes, Implanted; Electromyography; Genital Diseases, Male; Humans; Inguinal Canal; Inje | 2007 |
Two cases of idiopathic superior laryngeal neuralgia treated by superior laryngeal nerve block with a high concentration of lidocaine.
Topics: Aged; Anesthetics, Local; Female; Humans; Laryngeal Nerves; Lidocaine; Male; Middle Aged; Nerve Bloc | 2007 |
Treatment of an acute severe central neuropathic pain syndrome by topical application of lidocaine 5% patch: a case report.
Topics: Administration, Cutaneous; Anesthetics, Local; Humans; Lidocaine; Male; Middle Aged; Neuralgia; Panc | 2008 |
Superior laryngeal neuralgia after acute laryngitis and treatment with a single injection of a local anesthetic.
Topics: Acute Disease; Adult; Anesthetics, Local; Epinephrine; Humans; Injections; Laryngeal Nerves; Laryngi | 2007 |
Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Choice Behavior; Chronic Disease; Female; Humans; Kapla | 2008 |
Lidocaine 5% patch for localized chronic neuropathic pain in adolescents: report of five cases.
Topics: Administration, Cutaneous; Adolescent; Anesthetics, Local; Child; Chronic Disease; Cicatrix; Female; | 2008 |
Unusual treatments for herpesvirus infections. II. Herpes zoster.
Topics: Acyclovir; Antiviral Agents; Dimethyl Sulfoxide; Double-Blind Method; Griseofulvin; Herpes Zoster; H | 1983 |
Pain relief in herpes zoster.
Topics: Adolescent; Adult; Aged; Analgesics; Bupivacaine; Drug Combinations; Female; Herpes Zoster; Humans; | 1983 |
Local anesthesia for Herpes Zoster.
Topics: Anesthesia, Local; Herpes Zoster; Humans; Lidocaine; Neuralgia; Pain | 1980 |
Occipital neuralgia in a football player: a case report.
Topics: Adult; Anesthetics, Local; Bupivacaine; Cervical Plexus; Diagnosis, Differential; Football; Headache | 1995 |
EMLA cream-induced allergic contact dermatitis: a role for prilocaine as an immunogen.
Topics: Aged; Dermatitis, Allergic Contact; Drug Combinations; Drug Hypersensitivity; Female; Humans; Lidoca | 1995 |
Treatment of the cutaneous pain of acute herpes zoster with 9% lidocaine (base) in petrolatum/paraffin ointment.
Topics: Acute Disease; Administration, Cutaneous; Adult; Drug Evaluation; Female; Herpes Zoster; Humans; Lid | 1994 |
Cases 1A and 1B. 1995 intravenous lidocaine infusion for chronic pain therapy.
Topics: Adult; Anesthetics, Local; Causalgia; Chronic Disease; Drug Monitoring; Herpes Zoster; Humans; Infus | 1996 |
Use of EMLA cream in the treatment of post-herpetic neuralgia.
Topics: Administration, Topical; Aged; Anesthetics, Local; Drug Combinations; Female; Herpesviridae Infectio | 1996 |
Skin blood flow abnormalities in a rat model of neuropathic pain: result of decreased sympathetic vasoconstrictor outflow?
Topics: Animals; Cold Temperature; Hindlimb; Hyperalgesia; Laser-Doppler Flowmetry; Lidocaine; Ligation; Mal | 1997 |
Tumescent infiltration of corticosteroids, lidocaine, and epinephrine into dermatomes of acute herpetic pain or postherpetic neuralgia.
Topics: Acute Disease; Anesthetics, Local; Epinephrine; Glucocorticoids; Herpes Zoster; Humans; Injections; | 1998 |
Sensitization of the nervous system, induced by two successive hindpaw inflammations, is suppressed by a local anesthetic.
Topics: Analysis of Variance; Anesthetics, Local; Animals; Carrageenan; Edema; Hindlimb; Inflammation; Injec | 1998 |
The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 1998 |
Follow-up of clinical efficacy of iontophoresis therapy for postherpetic neuralgia (PHN).
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Anti-Inflammatory Agents; Female; Herpes Zoster; | 1999 |
Differential efficacy of intravenous lidocaine in alleviating ipsilateral versus contralateral neuropathic pain in the rat.
Topics: Anesthetics, Local; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Functional Laterali | 1999 |
Lidocaine patch 5%.
Topics: Absorption; Administration, Cutaneous; Anesthetics, Local; Herpes Zoster; Humans; Lidocaine; Neuralg | 2000 |
Herpes zoster.
Topics: Anesthetics, Local; Antiviral Agents; Chickenpox; Herpes Zoster; Humans; Lidocaine; Neuralgia; Virus | 2000 |
A new treatment for postherpetic neuralgia.
Topics: Anesthetics, Local; Anti-Inflammatory Agents; Drug Therapy, Combination; Herpes Zoster; Humans; Inje | 2000 |
Intrathecal methylprednisolone for postherpetic neuralgia.
Topics: Anesthetics, Local; Anti-Inflammatory Agents; Drug Combinations; Head-Down Tilt; Herpes Zoster; Huma | 2001 |
Intrathecal methylprednisolone for postherpetic neuralgia.
Topics: Anesthetics, Local; Anti-Inflammatory Agents; Herpes Zoster; Humans; Injections, Spinal; Lidocaine; | 2001 |
Intrathecal methylprednisolone for postherpetic neuralgia.
Topics: Anesthetics, Local; Anti-Inflammatory Agents; Drug Combinations; Herpes Zoster; Humans; Injections, | 2001 |
Intrathecal methylprednisolone for postherpetic neuralgia.
Topics: Anesthetics, Local; Anti-Inflammatory Agents; Drug Combinations; Herpes Zoster; Humans; Injections, | 2001 |
Steroid shots may help pain after shingles.
Topics: Anesthetics, Local; Anti-Inflammatory Agents; Herpes Zoster; Humans; Injections, Spinal; Lidocaine; | 2001 |
[Usefulness of epidural administration of ketamine for relief of postherpetic neuralgia].
Topics: Aged; Analgesia, Epidural; Bupivacaine; Drug Therapy, Combination; Female; Herpes Zoster; Humans; In | 2001 |
Contralateral treatment with lidocaine reduces spinal neuronal activity in mononeuropathic rats.
Topics: Action Potentials; Afferent Pathways; Anesthetics, Local; Animals; Dose-Response Relationship, Drug; | 2001 |
The diagnosis and management of post-traumatic pain syndromes (causalgia).
Topics: Adolescent; Autonomic Nerve Block; Causalgia; Extremities; Female; Humans; Lidocaine; Lumbosacral Re | 1979 |
Occipital neuralgia.
Topics: Female; Headache; Humans; Lidocaine; Male; Neck; Neuralgia; Neuritis; Thoracic Outlet Syndrome | 1979 |
Shingles: a belt of roses from Hell.
Topics: Cortisone; Drug Combinations; Herpes Zoster; Humans; Lidocaine; Neuralgia | 1979 |
Causalgia.
Topics: Adrenergic Fibers; Causalgia; Ganglia, Autonomic; Humans; Lidocaine; Neural Pathways; Neuralgia; Spi | 1978 |
[Irritation of the anterior nerves of the abdominal wall--Ibrahim syndrome].
Topics: Abdominal Muscles; Diagnosis, Differential; Female; Genital Diseases, Female; Humans; Intercostal Ne | 1992 |
Prolonged relief of neuralgia after regional anesthetic blocks. A call for further experimental and systematic clinical studies.
Topics: Adolescent; Adult; Aged; Anesthesia, Local; Animals; Female; Humans; Lidocaine; Male; Middle Aged; N | 1990 |
Treatment for herpes zoster ophthalmicus: stellate ganglion block as a treatment for acute pain and prevention of postherpetic neuralgia.
Topics: Acute Disease; Aged; Aged, 80 and over; Autonomic Nerve Block; Bupivacaine; Female; Herpes Zoster Op | 1991 |
Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine.
Topics: Adult; Aged; Carbamazepine; Female; Humans; Lidocaine; Male; Mexiletine; Neuralgia; Peripheral Nerve | 1991 |
Another headache.
Topics: Anesthesia, Local; Headache; Humans; Lidocaine; Neuralgia; Physicians, Family | 1991 |
EMLA cream and herpetic neuralgia.
Topics: Anesthetics, Local; Drug Combinations; Herpes Zoster; Humans; Lidocaine; Lidocaine, Prilocaine Drug | 1991 |
Topical lidocaine reduces pain in post-herpetic neuralgia.
Topics: Administration, Topical; Herpes Zoster; Humans; Lidocaine; Neuralgia; Pain Measurement; Palliative C | 1989 |
EMLA cream in the treatment of post-herpetic neuralgia. Efficacy and pharmacokinetic profile.
Topics: Administration, Topical; Aged; Aged, 80 and over; Analgesics; Drug Combinations; Female; Herpes Zost | 1989 |
Topical lidocaine for relief of superficial pain in postherpetic neuralgia.
Topics: Administration, Topical; Aged; Bandages; Drug Evaluation; Female; Herpes Zoster; Humans; Lidocaine; | 1989 |
Managing the pain of herpes zoster.
Topics: Adult; Aged; Doxepin; Female; Herpes Zoster; Humans; Lidocaine; Male; Middle Aged; Nerve Block; Neur | 1986 |
Xylocaine treatment for acute herpes zoster.
Topics: Herpes Zoster; Humans; Injections, Intradermal; Lidocaine; Neuralgia | 1986 |
[Perivasal anesthetic infiltration as a simple method for peripheral sympathetic blockade in pain states of the extremities (sympathalgias)].
Topics: Afferent Pathways; Arm; Autonomic Nerve Block; Bupivacaine; Dose-Response Relationship, Drug; Humans | 1985 |
A treatment of herpes zoster.
Topics: Acute Disease; Adolescent; Adult; Aged; Autonomic Nerve Block; Female; Herpes Zoster; Humans; Lidoca | 1985 |
The management of chronic pain syndromes in the upper extremity.
Topics: Analgesia; Arm; Causalgia; Electric Stimulation Therapy; Female; Humans; Lidocaine; Male; Nerve Bloc | 1974 |
Management of post-traumatic pain syndromes: report of 113 cases.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Arm Injuries; Autonomic Nerve Block; Causalgia; C | 1973 |
The management of neuralgias complicating herpes zoster.
Topics: Age Factors; Aged; Anesthesia, Conduction; Female; Ganglia, Autonomic; Herpes Zoster; Humans; Lidoca | 1973 |
Treatment of pain: organization of a pain clinic: treatment of acute herpes zoster.
Topics: Acute Disease; Adolescent; Adult; Aged; Anesthesia, Conduction; Child; Follow-Up Studies; Ganglia, A | 1973 |
[Intercostal neuralgia following thoracic surgery].
Topics: Anesthesia, Local; Humans; Injections, Intramuscular; Lidocaine; Neuralgia; Pneumothorax, Artificial | 1971 |
Posttraumatic sympathetic dystrophy. Dissociation of pain and vasomotor changes.
Topics: Angiography; Blood Flow Velocity; Child; Epinephrine; Foot; Humans; Injections, Spinal; Leg Injuries | 1971 |
[On the treatment of rheumatic conditions in metabolic diseases using Dexamed-Butazone].
Topics: Adult; Dexamethasone; Female; Flavonoids; Humans; Lidocaine; Male; Middle Aged; Neuralgia; Phenylbut | 1969 |
[Types of canalar neuralgia: value and technics of local injections].
Topics: Glucocorticoids; Humans; Injections; Lidocaine; Methods; Nerve Compression Syndromes; Neuralgia | 1970 |
[Clinical study of the action of Liocausyth].
Topics: Adolescent; Adult; Aged; Analgesics; Anti-Inflammatory Agents; Humans; Joint Diseases; Lidocaine; Mi | 1969 |